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Rho-associated kinases ROCK1 and ROCK2 are serine/threonine kinases that are 
downstream targets of the small GTPases RhoA, RhoB, and RhoC. They play a 
critical role in the pathogenesis of myocardial fibrosis; however, their specific function 
in cardiac fibroblasts (cFB) remains unclear. Remodelling processes in the diseased 
heart propels the transition of cFBs to a myofibroblast phenotype exemplified by 
increased proliferation, migration and synthesis of extracellular matrix (ECM) 
proteins. Therefore, we sought to investigate whether ROCK1 and ROCK2 protein 
signalling intermediates have an impact on cFB characteristics in isolated cells and 
engineered cardiac tissue. 
 
Knockdown of ROCK1 and ROCK2 and inhibition of ROCK1/2 activity altered cFB 
morphology, disrupted cytoskeletal structures, and increased adhesion velocity. In 
line, absolute number and area of focal adhesions was increased in ROCK1 and 
ROCK2 knockdown cells. Moreover, the double knockdown and inhibition of 
ROCK1/2 attenuated proliferation of cFBs. Interestingly, downregulation of either 
ROCK1 or ROCK2 decreased migration velocity and absolute distance, whereas the 
double knockdown and inhibition of ROCK activity increased both. Destructive tensile 
strength measurement of a three-dimensional engineered tissue model composed of 
cFBs (engineered connective tissue, ECT) treated with ROCK inhibitors showed that 
rigidity was significantly reduced compared to control tissues. This suggests that 
ROCK1 and ROCK2 influence the regulation and turnover of the ECM and thus 
viscoelastic properties of engineered tissues. Indeed, qPCR analysis of ROCK 
inhibitor-treated ECT showed that both ROCKs are involved in the regulation of 
several ECM proteins, including elastin and its degrading enzyme MMP12. In 
contraction measurements, human engineered heart muscle (hEHM) treated with 
ROCK inhibitors developed a significantly lower force of contraction per cross 
sectional area than control hEHM, whereas in the rat model (rEHM) no change in 
force of contraction could be detected. This demonstrates that ROCKs influence 




Die Rho-abhängigen Kinasen ROCK1 und ROCK2 gehören zu den Serin/Threonin-
Kinasen und sind Effektoren der kleinen GTPasen RhoA, RhoB und RhoC. Beide 
Kinasen spielen eine wichtige Rolle in der Pathogenese der kardialen Fibrose. 
Allerdings ist über ihre spezifische Funktion in kardialen Fibroblasten, den 
vorrangigen Zelltypen in fibrotischen Prozessen, bisher wenig bekannt. Strukturelle 
Umbauprozesse im Herzen sind charakterisiert durch die Differenzierung von 
kardialen Fibroblasten in sogenannte Myofibroblasten. Myofibroblasten zeichnet eine 
gesteigerte Proliferation und Migration aus; außerdem sezernieren diese Zellen 
vermehrt extrazelluläre Matrix. Aus diesem Grund sollte in dieser Arbeit untersucht 
werden, inwiefern ROCK1 und ROCK2 einen Einfluss auf spezifische Fibroblasten-
Charakteristika in isolierten Zellen und künstlichen Gewebemodellen haben.  
Der spezifische Knockdown von ROCK1 und ROCK2, bzw. ROCK Inhibition führte 
auf zellulärer Ebene zu einer Veränderung der zellulären Morphologie und des 
Aktinzytoskeletts in kardialen Fibroblasten. Außerdem konnte beobachtet werden, 
dass die kardialen Fibroblasten schneller adhärierten. Dies ging mit einer Zunahme 
der absoluten Anzahl und Größe der Fokaladhäsionen einher. Der doppelte 
Knockdown sowie die Inhibition beider Kinasen führte zu einer verringerten 
Proliferation der Zellen. Die planare Migration der kardialen Fibroblasten wurde durch 
einen spezifischen ROCK1 und ROCK2 Knockdown verringert, interessanterweise 
jedoch durch einen doppelten Knockdown bzw. die Inhibition der Kinasen gesteigert. 
Analysen der Zugfestigkeit künstlicher Gewebemodelle bestehend aus kardialen 
Fibroblasten (engineered connective tissue, ECT), die mit ROCK Inhibitoren 
behandelt wurden, zeigten eine reduzierte Steifigkeit im Vergleich zu 
Kontrollgeweben. Dies zeigte, dass ROCK1 und ROCK2 einen Einfluss auf die 
biomechanischen Eigenschaften künstlicher Gewebemodelle haben, mutmaßlich 
durch die Beeinflussung von Produktion und Abbau der extrazellulären Matrix. Dies 
konnte durch qPCR Analysen teilweise bestätigt werden. Mit ROCK Inhibitor 
behandelte ECT zeigten beispielsweise eine verringerte Elastin-Expression, 
wohingegen die Expression der Elastin-abbauenden Matrix-Metalloprotease MMP12 
erhöht war. In Kontraktionsexperimenten künstlicher Herzgewebe (engineered heart 
muscle, EHM), die mit ROCK Inhibitoren behandelt wurden, zeigte sich außerdem 
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eine verringerte Kontraktionskraft im Vergleich zu Kontrollgeweben im humanen 
Modell, wohingegen im Ratten Modell (rEHM) eine ähnliche Kraft beobachtet werden 
konnte. Dies zeigte, dass auch die Kontraktionsfähigkeit künstlicher Herzgewebe von 





1.1 Cardiovascular diseases 
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality 
worldwide, accounting for an estimated 31% of all deaths [1]. 
 
CVDs involving an imbalance between cardiac output and metabolic demands of the 
body may result as a consequence of cardiomyocyte (CM) death or dysfunction. This 
is typical after a myocardial infarction (MI) whereby reduced contractility (systolic 
dysfunction) and/or insufficient filling of the heart with blood (diastolic dysfunction) 
can be detected. During disease progression, pathological cardiac remodelling 
occurs involving morphological and functional changes. These include CM 
hypertrophy, along with apoptotic/necrotic CM death, cardiac fibrosis, chronic 
inflammation, and dilation of the heart [2]. 
 
Cardiac fibrosis is a complex mechanism involving the transdifferentiation of cardiac 
fibroblasts (cFB), endothelial cells, and other cell types into myofibroblasts, 
concomitant with excess deposition of extracellular matrix (ECM) proteins [3]. In 
addition to physiological alterations following a MI, fibrosis and the formation of a 
fibrotic scar causes collagens to substitute apoptotic/necrotic CM in an attempt to 
preserve the structural integrity of the heart. Fibrosis then leads to increased 
mechanical stiffness, which contributed to and deteriorates systolic and diastolic 
function and results in a vicious cycle towards decompensated heart failure [2, 4]. 
 
Despite our enhanced mechanistic understanding of heart diseases, it is still not 
possible to reverse the effects of pathological cardiac remodelling. Current therapy 
for heart failure, including -adrenergic receptor blockers, angiotensin-converting 
enzyme (ACE) inhibitors, diuretics and aldosterone antagonists, only target heart 
failure symptoms and do not address the underlying aetiology. Optimally, such 
therapies would stimulate CM proliferation and regeneration of scar tissue [5, 6]. The 
majority of our understanding stems from work focussed on CM, but recent studies 
have increasingly implicated non-myocyte cell populations, including cFBs, as major 
determinants in these pathological processes. 
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1.2 Origin and function of cardiac fibroblasts in the heart 
Fibroblasts are cells of mesenchymal origin and can be found in all vertebrate organs 
[7]. In the heart, cFBs make up to 70% of the cell content depending on species [8]. 
They are morphologically flat and spindle-shaped in culture with a prominent Golgi 
apparatus, but usually lack a basement membrane [7, 9]. 
 
A significant issue is the absence of a specific marker for cFBs. Three proteins that 
are commonly used for this purpose are the collagen receptor discoidin domain 
receptor 2 (DDR2), the intermediate filament vimentin, and the filament-associated 
calcium-binding protein fibroblast specific protein 1 (FSP-1) [10, 11]. However, all 
these markers lack fibroblasts specificity [9, 10, 12]. The lack of a specific marker 
might stem from cFBs being highly heterogeneous as they originate from several 
sources [9, 10]. During cardiac development, epicardium-derived cells undergo 
epithelial-mesenchymal transition (EMT) and differentiate into fibroblasts; a process 
driven by transforming growth factor  (TGF) and periostin [13-15]. Moreover, 
endothelial cells of the endocardium have been shown to transdifferentiate into 
fibroblasts in a process called endothelial-mesenchymal transition (EndMT) [16]. An 
additional source of fibroblasts are fibrocytes that derive from the bone marrow, and 
can be recruited to the site of injury following a MI [11]. 
 
cFBs play critical roles in maintaining the homeostasis of the ECM and normal 
cardiac function by participating in cardiac development, secretion of 
stimulatory/inhibitory molecules and remodelling processes. As such, cFBs secrete 
ECM proteins (predominantly collagen I, collagen III, and fibronectin) to provide a 
scaffold for other cell types [17]. They also secrete matrix metalloproteases (MMPs) 
that degrade ECM proteins ensuring proper ECM turnover [18]. cFBs also produce 
and secrete a number of growth factor and cytokines that can act in an autocrine or 
paracrine manner [7]. 
Moreover, cFBs are coupled to CM via connexin gap junctions (Cx40, Cx43, Cx45) 
that are vital for proper electrical conduction [19, 20]. cFBs are also connected to the 
ECM via integrins and can integrate their contractile properties on the intracellular 
collagen network, thereby subsequently exerting mechanical forces on CM. Their 
high membrane resistance permit cFBs to conduct electrical signals and form an 
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insulating layer between the atria and ventricles; this ensures proper and sequential 
contraction in the different areas of the heart [21]. 
 
Cumulatively, it is becoming more appreciated that cFBs partake a pivotal role in 
maintaining proper function of the myocardium by providing structural, 
biomechanical, and electrical support. 
 
 
1.3 The cardiac myofibroblast 
cFBs in the healthy heart are usually considered quiescent, although they play an 
important background role in maintaining overall homeostasis. Nevertheless, cFBs 
may be activated to myofibroblasts by various stimuli such as an overly active renin-
angiotensin-aldosterone system (RAAS) and TGF agonism. TGF-β is thought to be 
the major factor in the transdifferentiation of cells into myofibroblasts, promoting 
proliferation, migration, and ECM production [22]. In the first phase after an acute 
injury, TGF-β is considered to have a beneficial, protective role. However, 
continuously high TGF-β secretion leads to excess deposition of ECM resulting in 
cardiac muscle stiffening accompanied by impaired contractile performance [23, 24]. 
The RhoA/myocardin-related transcription factors (MRTF)/serum response factor 
(SRF) pathway which itself can be activated via TGF signalling through G protein 
coupled receptors or mechanical tension is another important mechanism [25-28]. 
RhoA signalling then leads to activation of its effectors ROCK and mDia, both 
influencing actin dynamics and cytoskeletal organisation [29, 30]. Also, transcriptional 
activity can be regulated through MRTF operating as co-activators for the SRF. 
Promoter regions of genes important in myofibroblast transdifferentiation and 
functionality are highly enriched for SRF binding sites [31, 32]. 
Myofibroblasts can also originate from epithelial-like and endothelial cells undergoing 
EMT and EndMT, respectively. They can also stem from fibrocytes from the bone 





Figure 1: Origin of myofibroblasts 
Cellular sources of myofibroblasts in acute (left) and chronic injury scenarios (right) [32]. 
After an acute MI, cFBs have been demonstrated to pass through a two-stage 
differentiation process into myofibroblasts. In the first, “proto-myofibroblast” stage, 
actin stress fibres are forming and they increasingly secrete collagens and fibronectin 
[33]. Additionally, these proto-myofibroblasts show relatively fast adhesion site 
formation and turnover enabling them to migrate into the wounded area [33, 34]. 
Approximately 20-30 h later, the second stage is initiated defined by a prominent 
stress fibre network due to the expression of -smooth muscle actin (SMA) and the 
development of a strong contractile phenotype [33]. 
Mature myofibroblasts are characterised by certain features such as the de novo 
expression of SMA and a spindle-shaped morphology with protruding dendritic-like 
processes [26, 34]. Defining markers for myofibroblasts are the hyper-secretion of 
ECM proteins like periostin, collagen I, collagen III, and fibronectin [33, 35]. This is 
important for fibrotic scar formation in wound healing and, in case of a MI, prevents 
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rupture of the ventricular wall [36-38]. Simultaneously myofibroblasts secrete ECM 
degrading MMPs that assist in migration within the scar to the repair site. 
 
Myofibroblasts are also an important source of bioactive auto- and paracrine acting 
molecules. Upon injury, myofibroblasts start to build an inflammatory environment by 
secreting cytokines, interleukins (IL), and recruiting neutrophils and macrophages to 
clear the injured area of apoptotic/necrotic cells [39]. Where acute cardiac 
remodelling is activated, myofibroblasts secrete tumour necrosis factor-α (TNF-α), IL-
1β, IL-6, and TGF-β. TNF-α was also demonstrated to participate in myofibroblast 
invasion, MMP secretion, and proliferation, whereas IL-6 acts as a stimulus for CM 
hypertrophy [40, 41]. 
 
After stabilisation of the injury, a number of myofibroblasts become senescent or 
undergo apoptosis [42-44]. However, the fate of the remaining myofibroblasts is not 
well understood. They may continue producing and secreting ECM through self-
reinforcing molecular signalling pathways leading to a vicious cycle of myofibroblast 
activation. In this scenario, TGF-β acts as a pro-survival stimulus of myofibroblasts. 
An enhanced understanding of the molecular mechanisms that drive these processes 
may aid in finding therapeutics that stop or prevent myofibroblast activation in chronic 
disease states [32]. 
 
 
1.4 Rho-associated kinases ROCK1 and ROCK2: Expression and structure 
The Rho-associated kinases ROCK1 (Rok-β) and ROCK2 (Rok-α) belong to the 
family of serine/threonine AGC kinases that are named after the protein kinase A, G, 
and C family members. They were first described as downstream mediators of the 
monomeric GTPase RhoA [45, 46]. ROCK1 and ROCK2 are encoded by two 
different genes and consist of 1354 and 1388 amino acids, respectively [47]. A 
schematic overview of ROCK1 and ROCK2 structure, including important 
phosphorylation and cleavage sites for activity regulation are summarised in Figure 
2. In general, ROCK1 and ROCK2 share 65% identity in their amino acid sequence 
[48]. They are most divergent within their coiled-coil region (55% identity), but are 
90% homologous within their kinase domain; this explains their similar function and 




Figure 2: ROCK structure and modes of regulation. 
ROCK1 and ROCK2 consist of an N-terminally located kinase domain and a C-terminally 
located pleckstrin homology (PH) domain containing a cysteine-rich C1 domain (CRD). The 
region between the ROCK kinase domain and the PH domain forms a coiled-coil structure 
where the Rho binding domain (RBD) is located. Both are highly homologous and share 
overall 64% amino acid sequence identity. A splice variant of ROCK2 contains an insertion of 
57 amino acids following the RBD and is called ROCK2m. ROCK1 and ROCK2 can be 
activated by binding of RhoGTP to the RBD and through cleavage of ROCK1 by caspase-3 
and ROCK2 by granzyme B and caspase-2. Autophosphorylation of ROCK1 at Ser1333 and 
ROCK2 at Ser1366 reflects the activation status of the kinases. Phosphorylation of ROCK2 
at Thr967, Ser1099, Ser1133, or Ser1374 increased its activation status, whereas 
phosphorylation of Tyr722 decreases the ability of ROCK2 to bind to RhoA. Interaction of 
Thr405 of ROCK2 with the N-terminal extension of the ROCK2’s kinase domain is essential 
for substrate phosphorylation and kinase domain dimerisation [3]. 
ROCK1 and ROCK2 both contain an N-terminally located kinase domain, followed by 
a coiled-coil region and a Rho-binding domain (RBD; [47]). The RBD of ROCK1 and 
ROCK2 binds exclusively to the switch I and switch II regions of activated RhoA, B, 
and C [50, 51]. No difference in binding affinity of ROCK1 or ROCK2 for the RBD has 
been described. RhoA, B, and C are monomeric GTPases that act as a molecular 
binary switches by cycling between an inactive GDP-bound, and an active GTP-
bound state. The mechanism of RhoGTPase activation is, on the one hand, mediated 
by guanine nucleotide exchange factors (GEFs) that are responsible for the 
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exchange of GDP and GTP and, on the other hand, by GTPase activating proteins 
(GAPs) that stimulate the intrinsic hydrolytic GTPase activity of RhoGTPases [52]. 
 
A split PH-domain is located at the C-terminus including a cysteine-rich C1 domain. 
The PH-domain has been shown to play an autoinhibitory role on ROCK function as 
it sequesters the N-terminal kinase domain, thereby reducing its kinase activity. 
Binding of the PH-C1 tandem motif to membrane bilayers via positively charged 
surfaces on each domain regulates the cellular localisation of ROCK1 and ROCK2 
and leads to the activation of kinases by releasing the kinase domain from its close 
conformation (see 1.5) [53]. ROCK1 and ROCK2 bind to different lipids using their 
PH domain. ROCK2 preferentially binds to phosphatidylinositol (3,4,5)-trisphosphate 
and phosphatidylinositol (4,5)-bisphosphate, whereas ROCK1 does not [54]. 
 
There are also differences in ROCK1 and ROCK2 protein expression. In the mouse, 
ROCK1 and ROCK2 are ubiquitously expressed with highest expression of ROCK2 
in brain, muscle, heart, lung, and placenta [48]. In a recent review, Julian and Olson 
(2014) analysed the expression of both kinases based on expressed sequence tags, 
confirming the higher abundance of ROCK2 in heart and brain and suggesting a 
more prominent expression of ROCK1 in blood cells and the thymus [3, 55]. 
Moreover, a novel spliced variant of ROCK2 called ROCK2m was detected in 
skeletal muscle, heart, and skin from humans and mice. It contains a 57 amino acid 
insertion following the RBD. During myogenic differentiation, ROCK2m is expressed 
together with ROCK2. However, its regulation and function are unknown [56]. 
 
ROCK1 and ROCK2 were differentially located within the cell that may vary for 
dependent on cell type. For ROCK2, a cytosolic and nuclear distribution has been 
reported, as well as association with the centrosome, and actin and vimentin 
filaments [57-63]. In striated muscle, ROCK2 can be found at intercalated disks and 
the Z-disc [64]. ROCK2 was additionally found near the cleavage furrow in late 
mitosis, arguing for a role in the formation of the contractile ring during cytokinesis 
[65]. In contrast, ROCK1 was reported to be located in the cytosol, and to associate 
with centrosomes, the plasma membrane, cell-cell contacts and adhesions sites, and 




1.5 Mechanisms of ROCK activation 
1.5.1 General mechanisms of ROCK activation 
The common mode of activation for both ROCK1 and ROCK2 is the so-called 
“derepression”. The C-terminus, including the PH domain of ROCKs directly binds to 
the kinase interface, thereby acting in an autoinhibitory manner. Upon binding of the 
GTP-loaded active RhoA to the RBD, this autoinhibitory stimulus is removed, leading 
to an active “open” conformation of the kinase domain, thereby increasing the kinase 
activity. 
 
Several studies have shown that deletion of C-terminal portions lead to a 
constitutively active kinase [47, 69-72]. So far, it is not clear whether further 
phosphorylation or other posttranslational modifications play a role in the regulation 
or fine-tuning of ROCK kinase activity. However, ROCK1 and ROCK2 crystal 
structures revealed that unlike other kinases, phosphorylation of the activation loop is 
not required for full activity [71, 72]. Instead, autophosphorylation of ROCK1 at 
Ser1333 and ROCK2 at Ser1366 reflect the activation status of each kinase. 
Intriguingly, antibodies targeting these phosphorylation sites may assist in studying 
the activation of these kinases that is usually achieved via analysis of the 
phosphorylation of ROCK targets like myosin light chain (MLC) phosphatase [73, 74]. 
 
Additionally, ROCK1 and ROCK2 can form homodimers that are dependent on the 
N-terminal extension of the kinase domains, the kinase domains themselves, and the 
coiled-coil region. Through this homodimerisation, the kinase’s active sites face the 
same direction, possibly enabling interaction with substrate dimers [71, 72]. 
 
 
1.5.2 Specific mechanisms of ROCK1 activation 
ROCK1 and ROCK2 share common modes of activation but can also be regulated 
differently. ROCK1 can be cleaved by caspase 3 at a conserved C-terminal 
DETD1113/G sequence upon activation during early apoptosis. This cleavage leads 
to the removal of the autoinhibitory C-terminus and thus, a constitutively active 




Furthermore, ROCK1 can be inhibited indirectly via Rnd3/p190RhoGAP-dependent 
inhibition of Rho/ROCK signalling. Rnd3 itself is an atypical RhoGTPase as it can 
bind GTP, however, does not possess hydrolytic activity and is therefore not 
regulated by the classical GTP/GDP switch mechanism of typical GTPases [76]. 
Rnd3 can be inhibited by ROCK1-dependent phosphorylation at different 
phosphorylation sites, thereby inducing Rnd3 translocation from the membrane to the 
cytosol and reducing the ability to induce the formation of stress fibres [77-79]. 
Phosphoinositide-dependent kinase 1 (PDK1) competes with Rnd3 in binding to 
ROCK1 independent of protein phosphorylation. In the absence of PDK1, inhibition of 
Rho/ROCK signalling via Rnd3 dominates, resulting in decreased actomyosin 
contractility and motility in cancer cells [80]. 
 
 
1.5.3 Specific mechanisms of ROCK2 activation 
Similar to ROCK1, ROCK2 can be cleaved and activated by proteases. Granzyme B, 
which is released together with perforin from cytotoxic granules during induction of 
apoptosis in natural killer cells and cytotoxic T-cells, was reported to cleave ROCK2 
at the IGLD1131 sequence at the C-terminus, which is absent in ROCK1 [81, 82]. 
This cleavage was independent from caspases and resulted in a constitutively active 
ROCK2. Intriguingly, ROCK2 cleavage led to the activation of caspases and ROCK1 
cleavage [82]. Moreover, caspase-2 can cleave ROCK2 into a 140 kDa fragment 
leading to kinase activation [83]. 
 
Both ROCK1 and ROCK2 have similar hydrophobic motifs located near the C-
terminus of the kinase domain. Phosphorylation of these motifs promotes the active 
conformation of other members of the AGC protein kinase family leading to further 
activation. In contrast to ROCK1, Thr-405 in the hydrophobic motif of ROCK2 
interacts with the N-terminal extension of the kinase domain, and is essential for 
promoting substrate phosphorylation and kinase domain dimerisation [71, 72]. 
 
In addition, the peripheral clock gene BMAL1 was reported to modulate the 
expression and activity of ROCK2 by binding directly to the promoter of ROCK2 in a 
time-of-day-dependent manner, leading to time-of-day variances in ROCK2 activity. 
In accordance, BMAL1 deletion from smooth muscle in mice decreased myosin 
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phosphorylation in the mesenteric arteries and suppressed the time-of-day variations 
in response to agonist-induced vasoconstriction [84]. 
 
 
1.6 Pharmacological ROCK inhibitors 
Many compounds have been developed to interfere with ROCK activity, the most 
prominent are Fasudil (formerly HA-1077) and Y-27632. Both act as competitive 
antagonists for ATP at the kinase domain and are non-selective for ROCK1 or 
ROCK2 with IC50 values of 330 nM for Fasudil and 140 nM for Y-27632 in cell-free 
assays [85-87]. When used at higher concentrations, they also inhibit other kinases 
involved in the same cellular processes as ROCKs, as PKA (IC50 of 1.6 µM for 
Fasudil) or PKC (IC50 of 3.3 µM for Fasudil) [85, 88, 89]. Fasudil is activated in the 
liver to its metabolite hydroxyfasudil, which exerts a more specific action on ROCKs 
than Fasudil itself [90]. Fasudil is the only ROCK inhibitor approved for human use; 
first in 1995 in Japan and China for the prevention and treatment of cerebral 
vasospasm following subarachnoid haemorrhage. Since then, Fasudil has been used 
widely in various clinical studies and showed beneficial effects in patients with PAH, 
systemic hypertension, vasospastic angina, stroke, and heart failure [91-95]. 
 
As most studies show promising and beneficial effects of the use of Fasudil and Y-
27632 in various in vitro and in vivo studies, significant efforts were made to develop 
more potent and isoform-selective inhibitors for ROCK1 and ROCK2. 
 
A derivative of Fasudil is H1152P ([(S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl) 
sulfonyl]-hexahydro-1H-1,4-diazepine]), which shows a higher potency and specificity 
for ROCKs than Fasudil itself with an IC50 of 1.6 nM, while the IC50 for other kinases 
remained relatively constant. So far, H1152P has only been used in preclinical in 
vitro and in vivo studies [96]. 
 
In 2008, Boerma et al. described the first and only ATP-competitive ROCK2-selective 
inhibitor named KD-025 ([2-(3-(4-((1H-indazol-5-yl)amino)quinazolin-2-yl) phenoxy)-
N-isopropylacetamide; formerly SLx-2119), which effectively decreased CTGF 
expression in human dermal fibroblasts. KD-025 is approximately 200-fold more 
selective toward ROCK2 than ROCK1, with IC50 values of 105 nM for ROCK2 and 
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24 mM for ROCK1 [97]. In two studies, KD-025 already showed therapeutic potential 
for the treatment of ischemic stroke and autoimmune diseases [98, 99]. 
 
 
1.7 ROCK targets in the cardiovascular system 
The best characterised phosphorylation motifs for ROCK1 and ROCK2 are Arg/Lys–
X–Ser/Thr or Arg/Lys–X–X–Ser/Thr. They share this motif with many other AGC 
kinases, including PKA, PKG, and PKC [79, 100]. Due to their high homology, the 
function of both ROCKs has long been considered to be similar, and their specificity 
has not been completely analysed. The only substrate specific for one of the kinases 
is Rnd3, which is exclusively phosphorylated by ROCK1 [3, 78]. An overview of 
ROCK substrates in the cardiovascular system described in this thesis can be seen 
in Figure 3. 
 
Figure 3: ROCK targets in the cardiovascular system. 
Rho proteins can be activated by guanine nucleotide exchange factors (GEFs) that are 
themselves activated by receptor tyrosine kinases (RTKs), G protein-coupled receptors 
(GPCRs), cytokines and integrins. Rho-GTP subsequently activates ROCK1 and ROCK2, 
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both having a broad range of substrates and is responsible for diverse cellular responses. 
CIP-17, kinase C-potentiated phosphatase inhibitor of 17 kDa; ERM, ezrin-radixin-moesin; 
FHOD1, formin homology 2 domain-containing 1; GAP, GTPase activating protein; LIMK, 
LIM-kinase; MLC, myosin II regulatory light chain; MYPT1, myosin phosphatase target 
subunit 1; PTEN, phosphatase and tensin homolog deleted on chromosome 10 [3]. 
The best characterised ROCK substrate is the myosin phosphatase target subunit 1 
(MYPT1), a regulatory subunit of myosin light chain phosphatase (MLCP). MLCP and 
MYPT1 modulate the Ca2+-dependent phosphorylation of myosin light chain (MLC) 
by dephosphorylating MLC. This counteracts the activity of MLC kinase and leads to 
decreased contraction of smooth muscle cells (SMC) [3]. Species-dependent 
phosphorylation of MYPT1 at Thr697, Ser854, or Thr855 by ROCK indirectly 
increases net MLC phosphorylation and actomyosin contraction by reducing MLCP 
activity [101, 102]. Furthermore, myosin II is dissociated from MLCP [103]. ROCKs 
have also been demonstrated to directly phosphorylate MLC at Ser19, the same 
residue phosphorylated by MLCK, thus increasing actomyosin contractility [45, 104]. 
In adult rat ventricular CMs, increased phosphorylation of MYPT and MLC2 was a 
consequence of -adrenergic receptor stimulation. Additionally, Ca2+ sensitivity of 
tension was enhanced and PP1-myofilament association was decreased in a ROCK-
dependent manner [105]. 
 
ROCKs, together with other kinases like PKC, directly phosphorylate protein kinase 
C-potentiated phosphatase inhibitor of 17 kDa (CPI-17) at Thr-38, believed to be 
important in the regulation of SMC contraction [106]. Phosphorylation of CPI-17 by 
ROCK or PKC enhanced phosphatase inhibition by more than 1000-fold [107]. 
 
LIM kinases (LIMK) 1 and 2 are also well-characterised ROCK targets and are 
ubiquitously expressed [108]. Upon phosphorylation of LIMK by ROCKs, LIMK 
phosphorylates cofilin, thereby inhibiting its actin-depolymerising and actin-severing 
functions. This leads to an increase in actin filament formation [109, 110]. Cofilin itself 
is an important mediator during pathological remodelling of the heart. Mice that are 
haploinsufficient for cofilin-2 in CMs had a dilated heart with increased left ventricular 
volume, decreased wall thickness, and reduced contractile function. Additionally, 
myofibrils showed a disorganisation of actin structures, as well as a poorly organised 
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sarcomere [111]. RhoA/ROCK-dependent cofilin phosphorylation was reported to be 
present in adult CMs that were treated with adiponectin, an important regulator of 
peripheral energy metabolism. The resulting increase in vesicular trafficking of 
lipoprotein lipase to the surface of CMs suggests a role of ROCK in metabolic 
processes [112]. 
 
FHOD3, a diaphanous related formin involved in actin filament polymerisation, is a 
further known target of ROCKs. Specifically, ROCK1 has been shown to interact with 
and phosphorylate FHOD3, thereby activating it [113].  
 
Ezrin, radixin, and moesin (ERM) proteins that crosslink the plasma membrane with 
actin filaments, are phosphorylated by ROCKs in vitro. This is thought to occur at a 
threonine residue located in the last 34 C-terminal amino acid region, also important 
in actin binding [114]. Phosphorylation in this region impedes intramolecular and/or 
intermolecular head-to-tail association, thereby interfering with regulatory 
mechanisms important for their proper function [115]. Similar to CPI-17, ERM 
proteins can also be phosphorylated by PKC and in endothelial cells, PKC was 
shown to be the major kinase [116, 117]. However, phosphorylation by ROCKs has 
been shown to play a role in the ERM-dependent localisation of leukocyte adhesion 
molecules in a docking structure, and coordination of barrier function [118-120]. The 
adapter molecule Na+/H+ exchanger regulatory factor 2 (NHERF2) was reported to 
be important for the interaction with and phosphorylation of ERM proteins by ROCK 
[121]. In smooth muscle cells, ERM proteins were shown to be phosphorylated by 
ROCKs and PKC in response to vasoconstrictors, leading to binding of moesin to 
adaptor molecule EBP50 and regulating smooth muscle cell contractility [122]. 
 
 
1.8 Function of ROCK1 and ROCK2 in cardiac fibroblasts 
Only a limited amount of studies focusses on the function of ROCK1 and ROCK2 in 
cardiac fibroblasts. Recently, RhoA/ROCK signalling was linked to expression of 
collagen I and III, the main ECM components secreted by cardiac fibroblasts. 
Treatment of cultured cardiac fibroblasts with alendronate, a farnesylpyrophosphate 
synthase inhibitor, was shown to inhibit RhoA geranylgeranylation, thereby 
preventing collagen I gene and protein expression. This effect could be mimicked by 
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treatment with inhibitors of the RhoA/ROCK pathway [123]. In addition, the ROCK 
inhibitors Y-27632 and Fasudil were shown to inhibit prostaglandin F2- and 
hyperglycaemia-induced collagen I and III expression in rat cardiac fibroblasts [124, 
125]. RhoA/ROCK signalling has also been shown to regulate cardiac fibroblast 
migration as treatment with Fasudil impaired migration of neonatal rat cardiac 
fibroblasts on a planar surface [126]. In a different study, simvastatin reduced the 
TNF-induced migration of cardiac fibroblasts via ROCK inhibition and subsequent 
disruption of the actin cytoskeleton [127]. Moreover, RhoA/ROCK was associated 
with proliferation of human atrial myofibroblasts, as simvastatin reduced proliferation 
of these cells via inhibition of RhoA geranylgeranylation [128]. 
 
 
1.9 Function and regulation of ROCK1 and ROCK2 in human cardiovascular 
disease 
Increased ROCK activity has been demonstrated in various cardiovascular diseases, 
including hypertension, pulmonary hypertension, stable angina pectoris, vasospastic 
angina, heart failure, and stroke [91, 92, 94, 95, 129-131]. An overview of the 
involvement of ROCK in human cardiovascular disease can be seen in Figure 4 [3]. 
 
Hypertension is one of the leading health problems in the world and is characterised 
by elevated vascular contractility and arterial wall remodelling leading to 
atherosclerosis. As a consequence, arterial pressure is elevated due to an increased 
vascular resistance in the peripheral vascular system [3]. ROCK activity as a result of 
an upregulated RAAS and an increase in reactive oxygen species was detected in 
hypertensive patients and models [91, 132-138]. For example, treatment of 
hypertensive patients with Fasudil markedly decreased peripheral vascular 
resistance [91]. In line with that, ROCK inhibitor treatment of spontaneously 
hypertensive rats decreased the mean arterial blood pressure, whereas the systolic 
blood pressure remained the same [139]. Specifically, ROCKs were found to be 
involved in structural and functional alterations of blood vessels in these rats [140]. 
Moreover, certain polymorphisms in the ROCK2 gene were associated with a lower 
risk of developing hypertension in patients [141]. Thus, although ROCK inhibitors do 
not always lower blood pressure in hypertension and studies in ROCK KO models 
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regarding blood pressure regulation have been inconclusive, strong evidence for 
involvement of ROCK signalling in hypertension remains [3]. 
 
Figure 4: Involvement of ROCK1 and ROCK2 in cardiovascular disease. 
Activated ROCK1 and ROCK2 play a pivotal role in processes leading to cardiovascular 
diseases such as hypertension, pulmonary arterial hypertension (PAH), atherosclerosis, 
vasospastic angina, stroke, diabetes, cardiac ischemia/reperfusion (I/R) injury and heart 
failure. Where possible, a distinction between the function of ROCK1 and ROCK2 in the 
different processes is made [3]. 
Similarly, ROCKs have been implicated in PAH. Patients that received Fasudil 
showed acute pulmonary vasodilation [131]. Also, ROCK2 expression was increased 
in the media of pulmonary arteries and pulmonary arterial smooth muscle cells from 
patients with idiopathic PAH [142]. In addition, Fasudil reduced pulmonary 
hypertension, RV hypertrophy, pulmonary vascular remodelling and mortality in 
hypertensive rats. On the cellular level, VSMC proliferation was reduced, along with 




In addition, Fasudil showed beneficial effects in reducing angina, as the treatment 
increased maximum exercise time and reduced the number of angina attacks in 
patients suffering from stable angina [129]. Likewise, in patients with vasospastic 
angina, Fasudil alleviated coronary artery spasms and myocardial ischaemia induced 
by acetylcholine [92]. This is supported by findings in porcine models in which 
interleukin 1 was chronically applied to coronary arteries from the adventitia to 
induce inflammatory lesions. Treatment with Fasudil decreased the serotonin-
induced coronary hyperconstriction as a result of an increased activation of MYPT1 
[144-146]. Moreover, exogenous NO, which is widely given as an anti-anginal agent 
to dilate the vasculature, decreased ROCK activity in peripheral leukocytes whereas 
expression of ROCK protein was unaltered [147, 148]. ROCK activity in circulating 
peripheral leucocytes is usually measured by calculating the levels of phosphorylated 
MYPT1 to total MYPT1 [149]. 
 
Patients with acute heart failure show an enhanced ROCK activity, which decreases 
during the time course of the disease [150]. However, elevated ROCK activity in 
circulating leukocytes can still be detected in patients with chronic heart failure, along 
with systolic dysfunction [151]. In addition, congestive heart failure patients show an 
increased ROCK activity which might be associated with increased mortality risk 
[152]. In line with these findings, treatment of chronic heart failure patients with 
Fasudil decreased forearm vascular resistance and increased simultaneously 
increased forearm vasodilation [94]. However, no correlation between established 
heart failure markers like cardiac troponin I and brain natriuretic peptide and 
enhanced ROCK activity could be found [150]. On the other hand, increased ROCK 
activity was demonstrated to correlate with high N-terminal pro-B-type natriuretic 
peptide in myocardial infarction. Therefore, enhanced ROCK activity could be used 
as a biomarker to identify high risk patients with acute coronary syndrome [153]. The 
findings in patients suffering from heart failure are supported by several animal 
models. For example, hypertensive rats that develop congestive heart failure and 
were treated with Y-27632 exhibited reduced vascular remodelling and cardiac 
dysfunction compared to control rats [154]. Similarly, mice that underwent myocardial 
infarction operation and were treated with Fasudil showed increased LV function, 
accompanied by reduced CM hypertrophy, interstitial fibrosis, and inflammatory 
cytokine expression [155]. 
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Taken together these studies show that inhibition of ROCK activity might be 
cardioprotective. Indeed, findings in cultured CM from mouse and rat and mouse 
models also point in this direction. Upon inhibition of ROCK, there was improved 
cardiac contractility due to a reduced phosphorylation of cardiac troponin I/T254, 
which led to preserved expression of sarco/endoplasmic reticulum Ca2+-ATPase 2a 
(SERCA2a) [156]. CM hypertrophy was shown to be reduced as a result of a 
decreased angiotensin II and endothelin-I signalling [157-160]. Additionally, CM 
apoptosis was decreased by activation of PI3K/Akt and extracellular signal-regulated 
mitogen-activated protein kinase (ERK)/mitogen-activated protein kinase (MAPK) 
pathways, as well as suppression of the pro-apoptotic Bcl-2 family protein Bax [161, 
162]. Finally, cardiac fibrosis was found to be decreased by ROCK inhibition, likely 
due to decreased expression of fibrotic and inflammatory cytokines [163]. 
 
 
1.10 Genetic animal models of ROCK1 and ROCK2 
1.10.1 Global knockout of ROCK1 and ROCK2 
The global knockout (KO) of ROCK1 in C57BL/6 mice, first described by Shimizu et 
al. in 2005, reported a failure of eyelid and ventral body wall closure. Most mice died 
however soon after birth due to maternal cannibalisation. At the cellular level, actin 
cytoskeleton organisation was disturbed and MLC phosphorylation levels decreased 
[164]. 
 
In contrast, global KO of ROCK2 was more severe in mice with 90% dying in utero as 
a result of constrained embryo-placenta interaction. The few surviving mice were 
smaller directly after birth when compared to wild type (wt), however caught up soon 
after and did not exhibit histological changes [165]. 
 
Interestingly, the phenotype of both KO models seems to be partly dependent on the 
genetic background. The ROCK1 KO was more severe with a FVB background 
compared to the firstly described KO in C57BL/6, as 60% of mice died in utero [163]. 
Likewise, the disturbed embryo-placenta interaction was only present in C57BL/6 × 
129/SvJ mice, but not in CD-1 (C57BL/6 × Dba) background mice [166]. Similar to 
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the ROCK1 KO, ROCK2 KO mice with a C57BL/6 background also showed failure of 
eyelid and ventral body wall closure [167]. 
 
 
1.10.2 Effects of ROCK1 and ROCK2 knockout on the heart 
ROCK1 plays an important functional role in cFBs and CMs. Mice with a global KO of 
ROCK1 were subjected to transverse aortic constriction (TAC). TAC is the ligation of 
the transverse aorta and a model for aortic stenosis and pressure overload of the 
heart, resulting in cardiac hypertrophy and heart failure. Initially, TAC results in 
compensated hypertrophy of the heart, often associated with a temporary 
improvement of cardiac contractility. Nevertheless, due to the chronic hemodynamic 
overload the response becomes maladaptive over time, leading to cardiac dilatation, 
fibrosis, and heart failure [168, 169]. ROCK1 global KO mice subjected to transverse 
aortic constriction (TAC) were reported to have reduced perivascular and interstitial 
cardiac fibrosis after three weeks, but not one week post-ligation. Accordingly, 
expression and secretion of the pro-fibrotic cytokines TGF2, CTGF and ECM 
proteins decreased. However, KO of ROCK1 did not have an effect on cardiac 
hypertrophy [163]. 
 
The role of ROCK1 in cardiac fibrosis in mice with a CM-specific overexpression of 
Gq and KO of ROCK1 was apparent. Similar to TAC, Gq overexpression mimics 
pressure-overload induced cardiac hypertrophy. Also, decreased gene expression of 
TGF2 and CTGF were detected in these mice [163]. This was further supported by 
another transgenic model of Gq overexpression that attenuated left ventricular 
dilation, contractile dysfunction and CM apoptosis after ROCK1 KO, but did not 
reduce cardiac hypertrophy. However, the expression of hypertrophic markers was 
reduced by ROCK1 KO, suggesting ROCK1 might be able to modify cardiac 
hypertrophy [170]. 
 
In accordance, further studies showed that loss of ROCK1 aided in preventing the 
transition from cardiac hypertrophy towards heart failure. Usually, mice with an 
overexpression of Gq develop lethal cardiomyopathy after pregnancy or at 
senescence. However, after deletion of ROCK1 in Gq overexpressing mice, survival 
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improved and left ventricular dilation, wall thinning, and CM apoptosis were reduced. 
Moreover, contractile function was preserved after pregnancy and in 12-month-old 
mice. The authors also reported, that overexpression of ROCK1 in transgenic Gq 
mice resulted in an increase in CM apoptosis and development of decompensated 
cardiomyopathy, independent of pregnancy stress [162]. 
 
The role of ROCK1 in fibrotic processes was further apparent in haploinsufficient 
ROCK1 KO mice. Following TAC or myocardial infarction evoked by the ligation of 
the left anterior descending coronary artery, haploinsufficient ROCK1 KO mice 
exhibited less perivascular fibrosis. Treatment with angiotensin II or NG-nitro-arginine 
methyl ester (L-NAME) in wt mice led to a similar increase in systemic blood 
pressure elevation, increase in left ventricular wall thickness and mass, and 
hypertrophy relative to haploinsufficient ROCK1 KO mice. Regardless of surgical or 
pharmacological evoked stress, reduced perivascular fibrosis and a decrease in 
TGF2, CTGF, and collagen III was reported [171]. 
 
Expression of a C-terminally truncated active form of ROCK1 (ROCK11) in CMs 
increased cardiac fibrosis in these mice. Additional treatment with angiotensin II led 
to the development of fibrotic cardiomyopathy with diastolic dysfunction, elevated NF-
B and SRF-dependent TGF1 signalling. Cumulatively, this led to the activation of 
adjacent cFBs that could explain the observed fibrosis. However, replacement 
fibrosis due to enhanced CM death is another plausible reason [161, 172]. 
 
The interlinked mechanism between Rnd3 and ROCK1 has already been described 
in section 1.5.2. Global haploinsufficient Rnd3 mice are susceptible to left ventricular 
pressure overload at basal state. When subjected to TAC, they develop severe heart 
failure, accompanied with increased CM apoptosis, enhanced levels of cleaved 
caspase 3, and increased ROCK activity. By crossbreeding these haploinsufficient 
Rnd3 with global ROCK1 KO mice, all of the effects were diminished after TAC, 
suggesting that the Rnd3-ROCK1 signalling axis participates in CM apoptosis [173]. 
 
The role of ROCK1 in pathological remodelling processes during heart disease was 
further analysed using the ischemia/reperfusion cardiomyopathy (I/RC) model, in 
which the left anterior descending coronary artery was occluded and subsequently 
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unoccluded. Mice with ROCK1 KO did not develop I/RC-mediated myocardial 
dysfunction and showed reduced cardiac fibrosis. In addition, a lower number of 
CD34/CD45 positive cells was detected which are believed to be blood-borne 
monocytic fibroblast precursors that get attracted to the myocardium upon I/RC [174]. 
Also, their differentiation into fibroblasts was reduced in ROCK1 KO mice [175]. 
 
However, no CM or cFB-specific genetic KO model is available for ROCK1. 
Therefore, to date it is not possible to determine whether ROCK1 primarily functions 
in CMs, cFBs, or both [3]. 
 
In contrast to ROCK1, ROCK2 has an influence on cardiac hypertrophy in mice. CM-
specific ROCK2 KO mice showed no impairment under basal conditions, however, 
after TAC or angiotensin II infusion developed less cardiac hypertrophy, 
intraventricular fibrosis, cardiac apoptosis and showed decreased oxidative stress 
compared to wt mice. This might be due to the upregulation of four-and-a-half LIM-
only protein-2 (FHL2), which controls the inhibition of SRF and ERK signalling that 
are both involved in CM growth. After crossbreeding of haploinsufficient ROCK2 KO 
with global FHL2 KO mice and angiotensin II infusion, the mice showed the same 
extent of cardiac fibrosis as their wt counterparts [176]. 
 
ROCK1 and ROCK2 signalling in the heart partake in complex interlinked 
mechanisms. This was nicely shown in a study by Ikeda et al. in which two models of 
pressure overload were utilised: TAC to induce pressure overload in the left ventricle 
(LV) and pulmonary artery constriction (PAC), which simulates pressure overload in 
the right ventricle (RV). In the TAC model, ROCK1 and ROCK2 expression in the 
vascular wall and perivascular area was increased three and seven days after TAC, 
respectively. In contrast, after PAC only ROCK2 expression was increased during the 
first days in the RV, but not in the LV. Transgenic overexpression of a dominant 
negative Rho-kinase (DN-RhoK), which inhibits ROCK1 and ROCK2 function, led to 
fewer pathological changes upon TAC and PAC in the ventricles and improved 
survival of the mice. The beneficial effects might be due to the downregulation of 





1.11 Previous results 
In preliminary experiments, a knockdown of ROCK1 and of both kinases was 
established to study the role of ROCK1 and ROCK2 in cardiac fibroblasts. This was 
achieved using lentiviral-mediated gene transfer of ROCK-specific shRNAs.  
 
 
Figure 5: Lentivirus-mediated knockdown of ROCK1 and ROCK1/2 in neonatal rat 
cardiac fibroblasts (NRCF). 
(A)  Immunoblots of ROCK1 and α-tubulin in shROCK1 and shROCK1/2 compared to shscr-
NRCF, and quantification of the relative change in ROCK1 protein expression in shROCK1 
and shROCK1/2 compared to shscr NRCF. (B) Representative immunoblots of ROCK2 and 
α-tubulin and quantification of the relative change in ROCK2 protein expression in shROCK1 
and shROCK1/2 compared to shscr NRCF are shown (means ±SEM, n=6-8, *p<0.05 vs. 
shscr). 
Primary, neonatal cardiac fibroblasts from the rat (NRCF) transduced with a lentivirus 
targeting ROCK1 or ROCK1 and ROCK2 are referred to as shROCK1 and 
shROCK1/2 cells, respectively. A scrambled, non-targeting shRNA (shscr) was used 













85% in shROCK1 NRCF. In the double knockdown, ROCK1 and ROCK2 protein 
expression was reduced by about 40% and 70%, respectively (Figure 5). 
 
The ROCK knockdown NRFC were then further characterised and it was found that 
upon knockdown of ROCK1, as well as upon knockdown of both kinases, NRCF 
morphology was altered, as there was an increase in cell area of 45% when 
compared to shscr NRCF (Figure 6A). Additionally, the FBS-driven proliferation of 
NRCF stopped after downregulation of ROCK1 and ROCK2. Downregulation of 
ROCK1 alone did not change the proliferative behaviour (Figure 6B). 
 
 
Figure 6: Characterization of lentivirus-mediated ROCK1 and ROCK1/2 knockdown in 
NRCF. 
(A) Evaluation of cell morphology. Relative cell area of siROCK1 and shROCK1/2 compared 
to shscr NRCF is shown (means ±SEM, n=3, 30-50 cells each, *p <0.05). (B) Proliferation 
assay of shscr, shROCK1 and shROCK1/2 NRCF over a time course of 6 days 
(means ±SEM, n=8, measured in 4 technical replicates/experiment, * p<0.05). 
To assess the influence of ROCK signalling on properties of cFBs and CMs in a more 
physiological model than a 2D culture, two different models of engineered tissues 
were used. Firstly, engineered heart muscle composed of neonatal cardiac cells from 
the rat (rEHM) and collagen type I as a matrix was generated. The rEHM were 
allowed to consolidate for seven days in custom-made moulds and then transferred 
onto phasic stretchers for mechanical load, which is essential for functional rEHM 
formation and maturation. During this phase, rEHM were treated with the non-
selective ROCK inhibitors Fasudil (10 µM) and H1152P (3 µM). Isometric force 
measurement at increasing concentrations of Ca2+ revealed that Fasudil-treated 






rEHM had a significantly decreased resting tension when compared to control rEHM. 
This trend could also be observed in H1152P-treated rEHM (Figure 7A). 
 
 
Figure 7: Analysis of contractile and viscoelastic properties of engineered tissues. 
(A, B) Isometric force measurement of engineered heart muscle from cardiac cells of the rat 
(rEHM) that were treated with ROCK inhibitors Fasudil (10 µM) and H1152P (3 µM). Analysis 
of (A) the resting force and (B) the force of contraction (FoC) of rEHM at different calcium 
concentrations (means ±SEM, n =4, in total 8-14 rEHM per condition, * p<0.05 vs. control). 
(C, D) Rheological destructive tensile strength measurement of engineered connective tissue 
from NRCF (rECT) that were treated with ROCK inhibitors Fasudil (10 µM) and H1152P 
(3 µM). (C) Representative stress-strain curves and (D) changes in the Young’s modulus of 
control, Fasudil- and H1152P-treated rECT are shown (means ±SEM, n=4, * p<0.05, values 
illustrate numbers of rECT measured). 
In contrast, force of contraction (FoC) was significantly enhanced in H1152P-treated 
rEHM compared to control. A trend towards an improved contractility was also 
observed in Fasudil-treated rEHM (Figure 7B). However, a limitation of this 
experiment is, that the generated forces were not based on the cross-sectional area 
(CSA) of the tissues, which is important when comparing forces of muscles with 
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different CSA. Treatment with both ROCK inhibitors increased the CSA of rEHM 
when compared to control, however, was not quantified. 
 
Secondly, engineered connective tissue was generated from NRCF and collagen I 
(rECT) and rECT treated with Fasudil (10 µM) and H1152P (3 µM). Rheological 
destructive tensile strength measurement revealed that stress-strain curved of rECT 
treated with ROCK inhibitors had an extremely flat shape compared to control (Figure 
7C). Additionally, the Young’s modulus, which is a measure for the rigidity of 
materials, was significantly reduced by 80% for Fasudil- and 85% for H1152P-treated 




It is increasingly appreciated that cFBs are essential for maintaining homeostasis and 
functionality of the myocardium, but after transdifferentiation into myofibroblasts also 
play as critical role in cardiac fibrosis. We hypothesised that ROCK1 and ROCK2 
have an impact on cFB characteristics and are important mediators of myofibroblast 
differentiation. 
 
In my preliminary studies, it was demonstrated that the knockdown of ROCKs has an 
influence on the morphology and proliferative behaviour of neonatal cardiac 
fibroblasts. Moreover, it was determined that ROCK1 and ROCK2 might have an 
influence on the viscoelastic and contractile parameters of engineered tissue models. 
Therefore, the aims of this thesis were: 
 
I. To investigate the effects of specific ROCK1 and ROCK2 knockdown on cFB 
morphology, protein expression, proliferation, migration, production and 
secretion of extracellular matrix components; 
II. Elucidate the importance of ROCK1 and ROCK2 signalling on viscoelastic 
and contractile properties of murine engineered tissues further, and to 
transfer these findings into a human model; 





Wistar-Kyoto Rats, Charles River, Sulzfeld 
 
 
2.2 Eukaryotic cells 
Primary cells: 
hES2 wild type-derived cardiomyocytes (hES2 CM), kindly provided by the Stem Cell 
Unit – Göttingen (SCU-G) 
Neonatal rat cardiac fibroblasts (NRCF), see 3.1.1 for detailed isolation procedure 
Normal human cardiac fibroblasts (ventricle, NHCF-V), Cat. No. CC-2904, Lonza 
 
Cell lines: 
HEK293A: Human embryonic kidney, immortalized by adenovirus serotype 5 
TSA201: Human embryonic kidney, immortalized by SV-40 large T antigen 
 
 
2.3 Bacterial strains 
E.Coli DH10B (Life Technologies; Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR Δ(ara,leu)7697 araD139 galU galK 
nupG rpsL λ-) 
 
 
2.4 Chemicals, reagents and consumables 
All chemicals were purchased in highest quality available from AppliChem, Carl Roth, 






Table 1: Fine chemicals and reagents 
Reagent Company 
α-Myc agarose beads Sigma Aldrich 
Acrylamide solution rotiphorese gel 30 Carl Roth 
Ammonium persulfate (APS) AppliChem 
ATP Thermo Scientific 
[γ-32P]ATP PerkinElmer Health Sciences 
B.V. 
BamHI NEB 
Bradford reagent (Roti-Quant) Carl Roth 
Bromphenol blue Sigma Aldrich 
CDK7, unactive (C36-14G) SignalChem 
cOmplete Protease Inhibitor Cocktail Tablets Roche 
DAPI (4',6-diamidino-2-phenylindole) Sigma Aldrich 
DNA molecular weight standard (1 kb DNA 
ladder) 
Thermo Scientific 
DNA molecular weight standard (1 kb plus DNA 
ladder) 
Thermo Scientific 
DTT Sigma Aldrich 
Ethidiumbromide 10 mg/mL Sigma Aldrich 
EvaGreen® dye for qPCR Solis Biodyne 
Fasudil hydrochloride Biomol 
H1152P dihydrochloride Biomol 
Igepal CA-630 Sigma Aldrich 
Loading dye 6x (Agarose gel electrophoresis)  Thermo Scientific 
Lumi‐ LightPLUS Western Blotting Substrate Roche 
NdeI NEB 
p21CIP1 protein (C27-30G), GST tag SignalChem 
Paraformaldehyde (PFA) Sigma Aldrich 
peqGOLD Universal Agarose peqLab 
PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets 
Roche 
Ponceau-S Sigma Aldrich 
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Protein Marker „Roti‐ Mark Standard“ Carl Roth 
ROCK1, active (R10-11G), GST tag SignalChem 
ROCK2, active (R11-11G), GST tag SignalChem 
Roti‐ Block (Blocking reagent) Carl Roth 
Roti‐ Nanoquant (Bradford reagent) Carl Roth 
SLx-2119 MedChem Express 
Sodium dodecyl sulfate (SDS) AppliChem 
SR-3677 dihydrochloride Tocris 
Sucrose AppliChem 
SuperSignal West Femto Thermo Fisher Scientific 
Tetramethylethylenediamine (TEMED) Merck 
TRITC‐ Phalloidin Sigma Aldrich 
Triton-X 100 Carl Roth 
Trizol Life Technologies 
Tween-20 Carl Roth 
 
 
Table 2: Consumables 
Consumables Type  Company 
Cell culture flasks T75; T175 Sarstedt 
Cell culture plates 10 cm; 15 cm Sarstedt 
Cell culture multi wells 6 well; 12 well; 24 well Sarstedt 
Cell scraper 25 cm; 2-position blade Sarstedt 
Collecting tubes 15 mL; 50 mL Cellstar 
Cryotubes 1.8 mL NUNC 
Filter Tips 10 µL; 100 µL; 1000 µL Greiner Bio One 
Microscope cover glasses 22 mm  Thermo Scientific 
Microscope slides SuperFrost Plus Thermo Scientific 
Multi Tips 2 mL; 5 mL; 10 mL Eppendorf 
Nitrocellulose protran transfer 
membrane 
BA83 Schleicher & Schuell 





Pipette tips 10 µL; 100 µL; 1000 µL Sarstedt 
qPCR plates MicroAmp optical 384-well 
reaction plate 
Applied Biosystems 
Reaction vessels 0.5 mL; 1.5 mL; 2 mL Eppendorf 
Sterile pipettes 2 mL; 5 mL; 10 mL; 25 mL Sarstedt 
Ultracentrifuge tubes Polyallomer centrifugation 
tubes, 14 mL 
Beckman 






Table 3: Devices 
Device Type Company 
Blotting chamber Mini Trans-Blot Cell Bio-Rad Laboratories 
Automated multiparameter 
cell analysis machine 
Cellavista SynenTec 
Cell counter and analyzer CASY Model TTC Roche 
Centrifuges Centrifuge 5804R Eppendorf 
Megafuge 3.OR Heraeus Sepatech 
Chemiluminescence Imager ChemiDoc MP Biorad 
Freezing container Mr. Frosty Nalgene 
Gel electrophoresis chamber Mini-PROTEAN Tetra Bio-Rad Laboratories 




Microscope filter blue 
Microscope filter red 
Microscope filter green 
Microscope objective 4x 
Microscope objective 10x 

























Heating block Thermomixer comfort Eppendorf 
Incubators Bacteria; 37°C  SANYO 
Cell culture; 37°C; 5% CO2 Labotec 
Large scale shaker Innova 4300  Eppendorf 
Microplate reader Flex Station 3  MDS Analytical 
Technologies  




PCR machine Mastercycler gradient Eppendorf 
pH meter Inolab pH Wtw 
Power supply Power PAC HD Bio-Rad Laboratories 
qPCR machine ViiA™ 7 Real-Time PCR 
System 
Life Technologies 
Rheometer RSA-G2 TA Instruments 
Rocker Diomax 1030 Heidolph 
Rotor ultracentrifuge SW32.1 Swinging Bucket Beckmann 
Rotation shaker Reax 3 Heidolph 













Sterile hood Telstar Bio II A Prettl 
Table centrifuge Centrifuge 5415D Eppendorf 







Vortexer VF2 W. Krannich 
Water bath 2764 Eppendorf 




2.6 Cell culture media and additives 
Table 4: Additives for cell culture 
Reagent Company 
2-mercaptoethanol Sigma Aldrich 
Accutase solution Merck-Millipore 
Activin A (stock solution 10 µg/mL in 1x PBS with 
0.1% HSA) 
R&D systems 
Albumin, recombinant Sigma Aldrich 
B27 supplement (50x) Invitrogen 
B27 supplement minus insulin (50x) Invitrogen 
BMP4 (stock solution 10 µg/mL in 1x PBS with 
0.1% HSA) 
R&D systems 
CHIR (stock solution 10 mmol/L in DMSO) Stemgent 
Collagen I (bovine) Collagen solutions LLC 
Collagen I (rat tail) own production 
DMEM (Dulbeccos modified eagle medium) 
powder 
BD Biosciences 
DMEM GlutaMAX 1 g/L glucose, pyruvate Life Technologies 
DMEM GlutaMAX, 1 g/L Glucose Biochrom 
DMEM GlutaMAX 4.5 g/L glucose Life Technologies 
DNaseI stock solution (1 mg/mL) Calbiochem 
DPBS (Dulbeccos phosphate buffered saline),  
w/o calcium and magnesium chloride  
Life Technologies 
0.5 M EDTA solution Appli-Chem 
Fetal bovine serum (FBS)  Life Technologies 
FGF Preprotech 
Fibroblast growth medium-3 (FGM-3) BulletKit 
(CC-3131 & CC-4525) 
Lonza 
Hexadimethrine bromide (Polybrene) Sigma Aldrich 
Horse serum (HS) Life Technologies 
HSA Sigma-Aldrich 
IGF-1 Preprotech 
IMDM Life Technologies 
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IWP4 (stock solution 5 mmol/L in DMSO) Stemgent 
Knockout (KO) DMEM Invitrogen 
Knockout serum replacement (KSR) Invitrogen 
L-Ascorbic acid 2-phosphate sesquimagnesium 
salt hydrate 
Sigma Aldrich 
Lipofectamine RNAiMAX Transfection Reagent Life Technologies 
Non-essential amino acids (NEAA), 100x Life Technologies 
Penicillin-streptomycin (P/S), 100x  
(10000 U/mL Penicillin, 10000 µg/mL 
Streptomycin)  
Life Technologies 
PolyFect transfection reagent Qiagen 
Puromycin (10 mg/mL) Life Technologies 
RPMI 1640 GlutaMAX Invitrogen 
RPMI 1640 w\o D-Glucose & L-Glutamine Biological Industries 
RPMI powder Life Technologies 
Sodium DL-Lactate solution 50% in H2O Sigma Aldrich 
Sodium pyruvate Life Technologies 
TGF-β1 Preprotech 
Trypan blue (0.4%)  Fluka  
TrypLE Express Life Technologies 
Trypsin EDTA, 0.05%  Life Technologies 




Table 5: Cell culture media and solutions 
Isolation of neonatal cardiac cells 
Calcium and bicarbonate free 
Hanks with HEPES (CBFHH) 
40 mL NaCl stock (200 g/L) 
10 mL MgSO4 stock (20 g/L) 
10 mL KH2PO4 stock (6 g/L) 
10 mL Na2HPO4 · 2 H2O (5.95 g/L) 
10 mL Glucose dehydrate stock (100 g/L) 




Heat-inactivated FBS 50 mL FBS were incubated in a water bath at 
56°C for 30 min 
NCM (Non cardiomyocyte) medium 
 
DMEM GlutaMAX 1 g/L glucose 
10% FBS (v/v, heat inactivated) 
1% P/S (v/v) 
 
Neonatal Heart Dissociation Kit, 




Enzyme A (reconstituted with 1 mL buffer A) 
Enzyme D (reconstituted with 3 mL DMEM) 
Enzyme P (ready to use) 
NRCF culturing 
NRCF growth medium 
 
DMEM GlutaMAX 4.5 g/L glucose 
10% FBS active (v/v) 
1% P/S (v/v) 
1% NEAA (v/v) 
NRCF selection medium DMEM GlutaMAX 4.5 g/L glucose 
10% FBS (v/v) 
1% P/S (v/v) 
1% NEAA (v/v) 
1 µg/mL puromycin 




DMEM GlutaMAX 1 g/L glucose 
1% FBS active (v/v) 
1% P/S (v/v) 
1% NEAA (v/v) 
Serum-depleted NRCF medium 
 
DMEM GlutaMAX 1 g/L glucose 
1% P/S (v/v) 
HEK293A, Tsa201 culturing 
HEK293/TSA201 growth medium 
 
 
DMEM GlutaMAX 4.5 g/L glucose 
10% FBS heat-inactivated (v/v) 




DMEM GlutaMAX 4.5 g/L glucose 
0.5% FBS heat-inacitvated (v/v) 




FGM-3 FGM-3 Basal Medium 
10% FBS (v/v) 
Insulin 
Rh-FGF-B (r-human FGF-B) 
GA-1000 (Gentamycin, Amphotericin) 
hES2 wild type cardiomyocyte (hES2-wt CM) differentiation and culturing 
Cardiac specification medium CM basal medium 
5 µmol/mL IWP4 
CM basal medium RPMI 1640 GlutaMAX 
1% Sodium pyruvate 
1% P/S 
2% B27 supplement (added on day of use) 
200 µM L-Ascorbic acid 2-phosphate 
sesquimagnesium salt hydrate 
EDTA digestion solution 500 ml 1x PBS containing 0.45 g NaCl 
500 μl of 0.5 M EDTA solution 
sterile filter, keep aliquots at 4 °C  
hCM selection medium RPMI medium 1640, w\o D-Glucose, w\o L- 
Glutamine  
1% P/S (v/v)  
0.5% Sodium DL-Lactate solution 50% in H2O 
(v/v) 
50 mmol/L 2-mercaptoethanol 
hESC conditioned medium 50% hESC culture medium (v/v) 
50% hFF conditioned medium (v/v) 
10 ng/mL FGF 
hESC culture medium KO DMEM medium  
20% KSR (v/v) 
1% NEAA (v/v) 
1% L-Glutamine (v/v) 
1% P/S (v/v) 
10 ng/mL FGF 
hFF conditioned medium hESC culture medium 
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10 ng/mL FGF 
add onto hFFs for 48 hours  
Medsoderm-induced medium CM basal medium 
1 µmol/mL CHIR  
5 ng/mL BMP4  
9 ng/mL Activin-A  
5 ng/mL FGF 
Generation and culturing of engineered heart muscle from primary neonatal 
rat cardiac cells (rEHM) 
10x DMEM 13.3 g DMEM powder in 10 mL ddH2O; sterile 
filtered 
2x DMEM 20% 10x DMEM (v/v) 
20% HS (v/v) 
2% P/S (v/v) 
in ddH2O, sterile filtered 
rEHM medium DMEM GlutaMAX, 1 g/L Glucose (Biochrom) 
10% HS (v/v) 
1% P/S (v/v) 
 
Generation and culturing of engineered heart muscle from NHCF-V and hES2 
wt CM (hEHM) 
10x RPMI 1.04 g RPMI powder in 10 mL ddH2O; sterile 
filtered 
2x RPMI (serum-free) 20% 10x RPMI (v/v) 
8% B27 minus insulin (v/v) 
2% P/S (v/v) 
in ddH2O, sterile filtered 
Digestion medium 98 mL Accutase solution 
2 mL DNaseI stock solution  
Growth factors FGF (10 µg/mL in DPBS, 0.1% recombinant 
albumin) 
IGF-1 (100 µg/mL in DPBS, 0.1% recombinant 
albumin) 




VEGF (5 µg/mL in DPBS, 0.1% recombinant 
albumin) 
Serum-free base medium (SFBM) IMDM 
1% sodium pyruvate (v/v) 
1% P/S (v/v) 
300 µM L-Ascorbic acid 2-phosphate 
sesquimagnesium salt hydrate 
Serum-free maturation medium 
(SFMM) with TGF-β1 
 
SFBM 
4% B27 minus insulin 
10 ng/mL FGF 
100 ng/mL IGF-1 
5 ng/mL TGF-β1 
5 ng/mL VEGF 
Serum-free maturation medium 
(SFMM) without TGF-β1 
 
SFBM 
4% B27 minus insulin 
10 ng/mL FGF 
100 ng/mL IGF-1 
5 ng/mL VEGF 
Generation of engineered heart muscle from NRCF (rECT) and NHCF-V (hECT) 
2x DMEM 20% 10x DMEM (v/v) 
20% FBS (v/v) 
2% P/S (v/v) 
in ddH2O, sterile filtered 
Isometric force measurement 
Tyrode’s solution 120 mM NaCl 
0.2 mM CaCl2 
5.4 mM KCl 
1.05 mM MgCl2 
22.6 mM NaHCO3 
0.42 mM NaH2PO4 
0.1% Glucose (w/v) 




2.7 Bacterial media and additives 
Table 6: Bacterial media and additives 
Reagent Company 
Agar-agar AppliChem 
Agar plates 2.8 g Agar-Agar 
200 ml autoclaved LB medium 
50 μg/ml Carbenicillin 
Carbenicillin AppliChem 
LB medium 10 g Trypton 
5 g Yeast extract 
5 g NaCl 
→ ad 1 L with ddH2O; autoclaved 
SOB medium 20 g Tryptone 
5 g Yeast extract 
0.5 g NaCl 
ad 1 L with distilled H2O 
→ autoclaved 
10 mL MgCl2 stock (10 mM)  
10 mL MgSO4 stock (1 mM) 
Yeast extract AppliChem 
 
 
2.8 Buffers and solutions 
Table 7: Buffers and solutions 
Immunofluorescence 
4% paraformaldehyde (PFA) 40 g paraformaldehyde 
200 µL 10 N NaOH 
100 mL 10x DPBS-/- 
ddH2O to 250 mL, pH 7.0 with HCl 
0.2% Triton X-100 1 mL 10x Triton X-100 
ddH2O to 50 mL 
1x Roti block 5 mL Roti block 
ddH2O to 50 mL 
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Blocking buffer 5 mL Roti block 
1 mL 10x Triton X-100 
ddH2O to 50 mL 
Flow cytometry cell cycle analysis 
Phosphate-citrate buffer 192 mL 0.2 M Na2HPO4 
8 mL 0.1 M citric acid (pH 7.8) 
SDS-Page and immunoblot 
Lysis buffer (GST-Fish) 6 g Tris 
8.8 g NaCl 
0.4 g MgCl2 
100 mL Glycerol (v/v) 
10 mL Igepal CA-630 (v/v) 
ddH2O to 1 L, pH 7.4 with HCl 
Phosphatase inhibitor cocktail added prior 
to use 
4x SDS-PAGE sample buffer w/o 
glycerol 
10 mL β-Mercaptoethanol 
3.6 g Tris 
5.7 g SDS 
0.2 g Bromophenol blue 
ddH2O to 100 mL, pH 7.4 with HCl 
4x SDS-PAGE sample buffer w/ 
glycerol (Laemmli buffer) 
50 mL Glycerol 
10 mL β-Mercaptoethanol 
3.6 g Tris 
5.7 g SDS 
0.2 g Bromophenol blue 
ddH2O to 100 mL, pH 7.4 with HCl 
10x APS 1 g APS 
ddH2O to 10 mL 
10% SDS 10 g SDS 
ddH2O to 100 mL 
5x SDS-PAGE buffer 30.2 g Tris 
188 g Glycine 
10 g SDS (w/v) 
ddH2O to 2 L, pH 8.3 with HCl 
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1x SDS-PAGE buffer 400 mL 5x SDS-PAGE buffer 
ddH2O to 2 L 
1x Immunoblot buffer 6 g Tris 
28.8 g Glycine 
400 mL Methanol (v/v) 
H2O to 2 L, pH 8.4 
10x Tris-buffered saline (TBS) 24.2 g Tris 
175.3 g NaCl 
ddH2O to 2 L, pH 7.4 with HCl 
1 x TBS with tween-20 (TBST) 200 mL TBS 
2 mL Tween-20 
ddH2O to 2 L 
Ponceau-S solution 0.2 g Ponceau-S 
3 mL Acetic acid 
ddH2O to 100 mL 
In vitro kinase assay 
Gel fixing solution 35 mL Acetic acid 
100 mL Ethanol 
ddH2O to 400 mL 
2x Kinase buffer 40 mM MgCl2 
4 mM MnCl2 
60 mM Tris pH 7.4 
Co-Immunoprecipitation 
Immunoprecipitation lysis buffer 1% Triton X-100 
20 mM Tris, pH 8 
130 mM NaCl 
1 mM DTT 
Protease inhibitor cocktail 
Phosphatase inhibitor cocktail 
10 mM NaF 
DNA agarose gel electrophoresis 
50x TAE buffer 2 M Tris-HCl, pH 8 
5.7% Acetic acid (v/v) 
0.05 M EDTA 
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1x TAE buffer 20 mL 50x TAE buffer 
H2O to 1 L 
Formaldehyde agarose gel electrophoresis 
10x RNA gel buffer 200 mM 3-N-morpholino propanesulfonic 
acid (MOPS) 
50 mM Sodium acetate 
10 mM EDTA 
RNase free H2O to 1 L, pH 7.0 with NaOH 
1x RNA gel buffer 100 mL 10x FA gel buffer 
20 mL 37% Formaldehyde 
RNase-free H2O to 1 L 
5x RNA loading buffer 16 µL saturated aqueous bromophenol blue 
solution 
80 µL 500 mM EDTA, pH 8.0 
720 µL 37% Formaldehyde 
2 mL 100% Glycerol 
2.084 mL Formamide 
4 mL 10x FA gel buffer 




2.9.1 Primary Antibodies 
Primary antibodies were incubated over night at 4°C whilst shaking. 
 
Table 8: Primary antibodies for western blot and immunofluorescence 
Primary Antibody 
against 




1:3000 - monoclonal 1A4 
A 5228, Sigma Aldrich 
Mouse 
β-actin 1:5000 - AC-47, Sigma Aldrich Mouse 
c-myc  1:2000 - monoclonal, 




p21 1:200 - polyclonal C19, 
sc-397, Santa Cruz 
Rabbit 
ROCK1 1:500 - monoclonal,  
611136, BD  
Mouse 
ROCK2 1:200 - polyclonal, 
sc-5561, Santa Cruz 
Rabbit 
Tubulin 1:5000 - monoclonal B-5-1-2 
T 5168, Sigma Aldrich 
Mouse 
Vimentin 1:2000 - monoclonal V9 
V 6630, Sigma Aldrich 
Mouse 
Vinculin 1:2000 1:500 monoclonal hVIN-1 




2.9.2 Secondary antibodies for immunoblot analyses 
Secondary antibodies were incubated for 1 h at room temperature (RT) whilst 
shaking. 
 
Table 9: Secondary antibodies for immunoblot analyses 


















2.9.3 Secondary antibodies for Immunofluorescence analyses 





Table 10: Secondary antibodies for immunofluorescence analyses 
Secondary Antibody against Dilution Clone/Company Species 
AlexaFluor 488 anti-Rabbit 
conjugate 
1:500 111-545-003, Jackson 
Immuno Research 
Goat 
AlexaFluor 488 anti-Mouse 
conjugate 






Table 11: Kits 
Application Name Company 
cDNA synthesis RevertAid First Strand cDNA Synthesis 
Kit 
Life Technologies 
Endpoint PCR PrimeStar HS polymerase TaKaRa 










High Pure PCR Product Purification Kit Roche 
Plasmid DNA 
preparation 
Exprep mini kit GeneAll 
Plasmid DNA 
preparation 
Plasmid midi kit Qiagen 
Plasmid DNA 
preparation 
PeqGold XChange Plasmid Maxi Kit peqLab 
Total RNA 
preparation 












gct cc gga aca tga act gca 
ggt agt tga gct tca ggc cat 
Col1α1 for 
Col1α1 rev 
acg cca tca agg tct act gc 
act cga acg gga atc cat cg 
Col3α1 for 
Col3α1 rev 
cca tga ctg tcc cac gta agc ac  
gga ggg cca tag ctg aac tga aaa c 
CTGF for 
CTGF rev 
ccg ggt tac caa tga caa ta 
cac acc cca cag aac tta gc 
Decorin for 
Decorin rev 
gct att cct caa ggt ctg cc  
ctg cca ttt tcc aca acg gt 
Elastin for 
Elastin rev 
cag gag tca agg cca agg tt 
gcc act cca tag ggc agt tt 
GUSB for 
GUSB rev 
tac ttc aag acg ctg atc gcc 
atc acct cc aga tgc ccg ta 
HAS2 for 
HAS2 rev 
ctg ggc aga agc gtg gat ta 
aac atc tcc ccc aac acc tc 
LGALS3 for 
LGALS3 rev 
agc cca acg caa aca gta tca  
tga atg gtt tgc cgc tct ca 
LOX for 
LOX rev 
gct gca cca ttt cac cg tatt ag  
gtc caa aca cca ggt act gct t 
MMP2 for 
MMP2 rev 
tcc ccc gat gct gat act ga 
ccg cca aat aaa ccg gtc ctt 
MMP9 for 
MMP9 rev 
gga taa cga gtt ctc tgg cgt 
cac ggc agg agg tca tag gtc 
MMP12 for 
MMP12 rev 
ggt acc aga gcc aca cta tc 
tcc tgc ctc aca tcg tac ct 
PBGD for 
PBGD rev 
cct gaa act ctg ctt cgc tg 
ctg gac cat ctt ctt gct gaa 
ROCK1 for 
ROCK1 rev 
ggt gaa aca cca gaa gga gct gaa 
ttt gca cgc acc tgc tca ata tca c 
ROCK2 for 
ROCK2 rev 
ttc cca acc aac tgt gag gc 





aga gcc ctg gat acc aac ta 
tgt tgg ttg tag agg gca ag 
Vimentin for 
Vimentin rev 
gag agc acc ctg cag tca tt  




Table 13: Lentivirus plasmids 
Name Plasmid Coding for Company 
psPAX.2 psPAX.2 Lentiviral proteins (Gag, Rev, 
Tat) 
D. Trono Lab 
pMD2.G pMD2.G Glycoprotein of the human 
vesicular stomatitis virus 
D. Trono Lab 
shROCK1 pLKO.1 gca cca gtt gtg cct gat tta Open Biosystems 
shROCK1/2 pLKO.1 att tgt ttc ttc aag aga tgc Open Biosystems 
shscr pLKO.1 shRNA, no fit to any mammal 




Table 14: Overexpression plasmids 
Plasmid Provided by 
pCAG-myc-ROCK1 Prof. Shuh Narumiya 




Table 15: Software 
Analyses Software 
Confocal images Zen 2012 (Zeiss) 
Flow cytometry cell cycle analyses FACSDiva (BD) 
Image processing & analyses ImageJ 
Immunoblot ImageLab 5.1 (Biorad Laboratories) 
Immunofluorescence/Life cell imaging  Xcellence pro (Olympus) 
 
 44 
Migration assay (Life cell imaging) ImageJ 
Plug-in: manual tracking, 
chemotaxis assay 
Multi-mode microplate reader measurements SoftMax Pro 5.4 
Proliferation assay Cellavista 
qRT-PCR ViiA™ 7 Software (Life 
Technologies) 
Rheological measurements TRIOS (TA Instruments) 
Statistical evaluations GraphPad Prism 6, Microsoft Excel 




3.1 Cell biology methods 
3.1.1 Preparation of cardiac cells from neonatal rats 
Neonatal rat cardiac fibroblasts (NRCF) and cardiomyocytes (NRCM) were isolated 
using the Neonatal Heart Dissociation Kit, mouse and rat (Miltenyi Biotec) according 
to the manufacturer’s instructions. All steps were performed on ice. 40-60 neonatal 
Wistar rats (P0-P3) were decapitated, a thoracotomy performed, and the heart, 
including the vascular pedicle, was excised and transferred into a 10 cm cell culture 
dish containing CBFHH buffer. For a preparation containing ventricular cells only, the 
atria, vascular pedicle and remaining connective tissue was dissected. 
 
To remove adverse blood, the ventricles were washed twice with CBFHH. 
Subsequently, the ventricles were cut into small 1 mm³ pieces and again washed 
twice with CBFHH. Enzyme mix 1 and 2 were prepared as shown in Table 16. 
 
Table 16: Preparation of enzyme mix 1 and 2 for preparation of cardiac cells 
 Enzyme mix 1 Enzyme mix 2 
Number of neonatal 
rats 




40 125 µL 4600 µL 50 µL 25 µL 200 µL 
60 187.5 µL 6900 µL 75 µL 37.5 µL 300 µL 
 
Enzyme mix 1 was heated for 5 min at 37°C, then added to enzyme mix 2 (hereafter 
referred to as enzyme mix). The diced ventricular tissue was transferred to two 
gentleMACS C tubes; 2.5 mL or 3.75 mL of enzyme mix for 40 or 60 neonatal rat 
hearts respectively, was added to each tube. The tubes were inverted and the 
samples incubated for 15 min at 37°C. Subsequently, the tubes were attached onto 
the sleeve of the gentleMACS dissociator and the dissociation was started using the 
gentleMACS program htumor3.01. The incubation and dissociation steps were 
repeated three times. 
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The cells were resuspended in 7.5 mL of NCM medium and strained through 250 μm 
pore stainless steel mesh. The resultant cell suspension was centrifuged at 60 g for 
20 min, supernatant discarded and the pellet resuspended in 20 mL NCM medium. 
To determine cell number, 10 µL of the cell suspension were diluted 1:1 with 0.4% 
trypan blue solution, and counted using a Neubauer counting chamber. 
 
 
3.1.2 Separation of cardiac fibroblasts and cardiomyocytes 
To separate NRCF from NRCM, 8 · 106 cardiac cells were seeded on a 15 cm cell 
culture dish in ice-cold NCM medium and incubated for 45 min in a humidified 
incubator (37°C, 5% CO2). During this time the fibroblasts adhered to the cell culture 
dish, whereas cardiomyocytes remained mostly in the medium. The NCM medium 
containing non-cardiac fibroblasts was removed and changed to NRCF growth 
medium (see 2.6). NRCF were cultured according to 3.1.3 until they were confluent.  
 
 
3.1.3 Culturing, passaging and freezing of NRCF 
NRCF were cultured in NRCF growth medium in a humidified cell culture incubator at 
37°C, 5% CO2. Medium was replenished every second day. To passage NRCF’s, 
medium was aspirated, cells washed once with DPBS, and incubated with 0.05% 
trypsin-EDTA (2.5 mL/10 cm culture dish or 5 mL/15 cm culture dish and 175 cm2 
culture flask). After 3-5 min incubation at 37°C, detachment of the fibroblasts was 
monitored with a light microscope. The enzymatic activity of trypsin was halted by the 
addition of double the volume of NRCF growth medium. The cells were collected and 
centrifuged at 300 g for 5 min, supernatant discarded and the remaining cell pellet 
resuspended in NRCF growth medium. Cell number and viability were measured by 
electrical current exclusion using the CASY TT system (Roche). NRCF were seeded 
at the required density on new culture dishes, or used to construct rat engineered 
connective tissue (rECT). 
 
To freeze NRCF, cells were mixed with NRCF growth medium containing 10% 
DMSO, the suspension transferred into cryovials and placed into a “Mr. Frosty” 
 
 47 
freezing container. The cells were permitted to gradually freeze for 4-5 h at -80°C. 
NRCF were then transferred to -152°C for long-term storage. 
 
 
3.1.4 Thawing, culturing and passaging of HEK293A and Tsa201 cells 
HEK293A and Tsa201 cells were thawed in a 37°C water bath, diluted with 
HEK293A/Tsa201 growth medium (see 2.6), and seeded in an appropriate culture 
vessel. Medium was replenished the following day to remove residual DMSO and 
every second day thereafter.  
 
For passaging of HEK293A and Tsa201, medium was aspirated, cells washed once 
with DPBS, and incubated with 0.05% trypsin-EDTA (2.5 mL/10 cm culture dish or 
5 mL/15 cm culture dish and 175 cm2 culture flask) for 2 min at room temperature 
(RT). The enzymatic reaction was stopped by adding two volumes of 
HEK293A/Tsa201 growth medium. Cells were harvested, centrifuged (see 3.1.3), 
resuspended in HEK293A/Tsa201 growth medium, and cell number and viability 
were measured using the Casy TTS (see 3.1.3). HEK293A and Tsa201 were frozen 
for long-term storage as described in 3.1.3. 
 
 
3.1.5 Thawing, culturing and passaging of normal human cardiac fibroblasts 
from the ventricle (NHCF-V) 
NHCF-V were thawed in a 37°C water bath. The contents of the cryovial was 
transferred to a tube, the cryovial washed with 1 mL of Fibroblast growth medium-3 
(FGM-3) containing growth factors, cytokines, and supplements supplied by Lonza 
(see 2.6) and slowly added to the cells to avoid osmotic shock. Under constant 
shaking, another 8 mL of FGM-3 were added to the tube and the NHCF-V seeded in 
an appropriate cell culture vessel. Medium was exchanged the next day to remove 
residual DMSO and then every second day thereafter. NHCF-V were cultured in 
FGM-3 in a humidified cell culture incubator at 37°C, 5% CO2.  
 
To passage NHCF-V, medium was discarded, cells washed once with DPBS, and 
incubated with TrypLE Express reagent (6 mL/175 cm2 culture flask) for 3-5 min at 
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37°C. The enzymatic reaction was stopped by adding two volumes of FGM-3. Cells 
were harvested, centrifuged, resuspended in FGM3, and cell number and viability 
were measured using the Casy TTS (see 3.1.3). NHCF-V were seeded in the 
required density on new culture dishes, used for the construction of human 
engineered connective tissue (hECT), or human engineered heart muscle (hEHM).  
 
To freeze NHCF-V, cells were mixed with FBS containing 10% DMSO, cryovials 
were placed into a freezing container and transferred to -80°C to gradually freeze for 
4-5 h. NHCF-V were then transferred to -152°C for long-term storage. 
 
 
3.1.6 Culturing of human embryonic stem cell-derived cardiomyocytes 
The human embryonic stem cell line “hES2” was purchased from Embryonic Stem 
Cell International (Singapore). Differentiation of hES2-wt cells into cardiomyocytes 
(CM) was kindly performed by the stem cell unit Göttingen (SCU-G). In brief, human 
embryonic stem cells (hESCs) were initially cultured on irradiated human foreskin 
fibroblasts (hFFs) in hESC culture medium (see 2.7). For expansion and single cell 
adaptation, hESCs were passaged using EDTA digestion solution (see 2.7) and 
plated on feeder free Matrigel-coated plates (diluted 1:30 in DPBS) in a seeding 
density of 5  104 to 1  105 in hESC-conditioned medium (see 2.7). During 
differentiation into CM, medium was changed every other day. One day after plating, 
hESCs were rinsed once with CM basal medium and then cultured in mesoderm-
induction medium (see 2.7) for three days. Cells were again washed with CM basal 
medium and cultured in cardiac specification medium (see 2.7) for the following ten 
days. To obtain a pure population of CM, they were metabolically selected in CM 
selection medium (see 2.7) for further five days. Thereafter, hES2-wt CM were 
cultured in CM basal medium in a humidified cell culture incubator at 37°C, 5% CO2. 
Medium was exchanged every second day.  
 
For dissociation of hES2-wt CM, medium was removed, cells were washed twice with 
DPBS and incubated with accutase containing digestion medium (see 2.7) for 
5 to 15 min at RT. Detachment of hES2-wt CM was controlled using a light 
microscope and enzymatic reaction was stopped by adding three volumes of CM 
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basal medium. Cells were harvested, centrifuged, resuspended in CM basal medium, 
and cell number and viability were measured using the Casy TTS (see 3.1.3). 
 
 
3.1.7 Generation of lentivirus particles in Tsa201 
Stable knockdown of ROCK1 and ROCK2 was induced by lentiviral delivery of short 
hairpin RNAs (shRNAs) and RNA interference (RNAi). pLKO.1 HIV-based lentiviral 
vectors encoding for the respective shRNA constructs were purchased from Thermo 
Scientific. The pLKO.1 vectors also contained integration and packaging elements of 
lentivirus particles, a puromycin resistance cassette for selection of transduced cells, 
and a SV40 origin of replication (ori), enabling replication in cell lines expressing the 
large T antigen and allows high-level expression.  
 
Tsa201, a cell line derived from human embryonic kidney cells, are highly 
transfectable and express the SV40 large T antigen necessary for activation of 
plasmid expression via SV40 ori. To generate non-replicating transducing lentivirus 
particles, three separate plasmids for expression of lentiviral proteins and the 
transgene were co-transfected: pMD2.G encodes for a glycoprotein of the vesicular 
stomatitis virus, pPAX2 is a packaging plasmid containing the viral structural genes, 
and pLKO.1 contains the shRNA targeting either ROCK1, ROCK2, or the shRNA 
shscr (no target in the corresponding genome and thus used as a control). 
 
Tsa201 cells were cultured on 10 cm culture dishes in HEK293A/Tsa201 growth 
medium until 70% confluent. Medium was changed to HEK293A/Tsa201 serum-
reduced medium and transfection was performed according to the polyfect 
transfection reagent handbook (Qiagen). The transfection mix was prepared as 
shown in Table 17. After 10 min incubation at RT, 620 µL HEK293A/Tsa201 serum-
reduced medium was added to the reaction mix, which was then carefully added to 






Table 17: Transfection mix for generating lentivirus particles 
Reagent Amount 
Plasmid with GOI     3 µg 
psPAX.2     3 µg 
pMD2.G     2 µg 
Medium without antibiotics or serum 300 µL 
Polyfect   80 µL 
 
After 48 h and 72 h, the lentivirus particle-containing supernatants were harvested 
and replenished with fresh HEK293A/Tsa201 serum-reduced medium. The collected 
supernatants were pooled and filtered through a 45 μm syringe filter to remove cell 
debris. 
 
For concentration and purification of the lentivirus, harvested supernatants were 
transferred to a 14 mL ultracentrifuge tube containing 1 mL of 20% sucrose in TNE 
buffer and centrifuged for 4 h, 22,000 g, and 4°C. The virus containing sucrose 
solution was frozen in liquid nitrogen and stored at -80°C. 
 
 
3.1.8 Lentiviral transduction of NRCF to knockdown ROCK1 and ROCK2 
When required, the lentivirus particles were thawed on ice. NRCF were passaged 
according to 3.1.3 and seeded with NRCF growth medium containing the suitable 
virus and 8 µg/µL polybrene to improve the infection rate. After 48 h and 96 h, the 
medium was changed to NRCF selection medium containing 1 µg/mL puromycin. 
Seven days after infection, cells were transferred into multiwell dishes according to 
the experiments to be performed. 
 
 
3.1.9 Transfection of NRCF to knockdown ROCK1 and ROCK2 
Another application of RNAi is mediated by small interfering RNAs (siRNAs), which 
can be transfected into cells using various transfection reagents. 
NRCF were passaged according to 3.1.3 and cultured in NRCF growth medium on 
12-well plates until 70% confluent. Transfection of siRNAs was performed using 
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Lipofectamine RNAiMAX in Opti-MEM (Life Technologies). The transfection mix was 
prepared as shown in Table 18, combined, mixed thoroughly and incubated for 
20 min at RT. 
 
Table 18: Transfection mix for siRNA transfection into NRCF 
 Mix 1 Mix 2 








1 well (12-well plate) 1.1 µL 110 µL 3.3 µL 120 µL 
1 well (6-well plate) 2.75 µL 275 µL 8.25 µL 300 µL 
 
NRCF were washed twice with DPBS and medium was replaced with 300 µL or 
750 µL Opti-MEM per well of a 12-well or 6-well plate, respectively. After 20 min 
incubation, 200 µL (12-well) or 500 µL (6-well) of the transfection mix was added to 
the cells. After 6 h, the transfection medium was changed to NRCF growth medium 
and incubated for 48 h. 
 
 
3.1.10 Co-transfection of HEK293A for overexpression of ROCK1 and p21 
One day before transfection, 2 · 106 HEK293A cells were seeded on a 10 cm culture 
dish to achieve 70-90% confluent cells the following day. For transfection, 10 µg of 
plasmid DNA was mixed with 1 mL Opti-MEM and 20 µL TurboFect (Thermo Fisher). 
The transfection mix was briefly vortexed, incubated for 20 min at RT, added to the 
10 cm culture dish containing HEK293A cells and HEK293A/Tsa201 growth medium. 
The medium was exchanged after 4 h and the cells harvested after 48 h for 
subsequent immunoprecipitation (see 3.3.7). 
 
 
3.1.11 Proliferation assay 
The proliferation of NRCF was analysed over six days. 10,000 knockdown NRCF or 
wild type NRCF were seeded on 24-well plates with NRCF growth medium changed 
daily. Wild type NRCF were treated with 3 µM H1152P every day. Cells were then 
fixed with 4% paraformaldehyde (PFA) in DPBS for 15 min after 24 h (=Day 0) and 
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on days 1, 2, and 6. After two washing steps with DPBS, cells were incubated with 
Hoechst 33342 (10 µg/mL) in DPBS for 30 min. Automated evaluation of cell 
numbers was performed using the Cellavista system (Roche). 
 
 
3.1.12 Adhesion assay 
Knockdown NRCF were seeded in NRCF growth medium on uncoated 12-well plates 
or coated with 1% collagen I in DPBS. After 20, 40 and 60 min, ten bright-field 
images per condition were taken using the time-lapse function of an inverted 
fluorescence microscope (Olympus) with a CM 10 T camera (Olympus) and 10x 
objective equipped with a humidified climate chamber at 37°C, 5% CO2. The number 
of adhered and non-adhered cells was counted and values expressed relative to the 
total cell number. 
 
 
3.1.13 Live cell imaging and migration assay 
Knockdown or wild type NRCF were seeded on 24-well plates. Wild type NRCF were 
treated with 3 µM H1152P for 24 h. Live cell imaging was performed in NRCF growth 
medium using the time-lapse function of an inverted fluorescence microscope 
(Olympus) with a CM 10 T camera (Olympus) and 10x objective equipped with a 
humidified climate chamber at 37°C, 5% CO2. Bright-field images were taken every 
20 min for 24 h. Cell tracking was performed using the manual tracking macro in 
ImageJ. Migration parameters were calculated using the chemotaxis plug-in for 
ImageJ provided by Ibidi. 
 
 
3.1.14 Transwell migration 
To analyse the ability for cells to migrate through pores, cell culture inserts with 8 µm 
porous membranes from Greiner Bio One (thincerts) were used. The thincerts were 
inserted into a 24-well plate and the wells filled with NRCF growth medium or NRCF 
serum-reduced medium. 5,000 knockdown NRCF in NRCF serum-reduced medium 
were seeded into one thincert and incubated for 24 h at 37°C, 5% CO2. After 24 h, 
the thincerts were washed once with DPBS and cells were fixed with 4% PFA in 
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DPBS for 15 min. After two additional washing steps with DPBS, the remaining cells 
were carefully removed from the top of the membrane using a cotton swab. The 
membrane was cut out, placed on a microscope slide and incubated with 
Hoechst 33342 (10 µg/mL) in DPBS for 30 min. Subsequently, the membranes were 
imaged using an inverted fluorescence microscope (Olympus) with a CM 10 T 
camera (Olympus) and 10x objective equipped with a humidified climate chamber at 




3.1.15 Generation of engineered heart muscle from isolated primary neonatal 
rat cardiac cells (rEHM) 
Neonatal rat cardiac cells were isolated from 0 to 3-day old neonatal rat hearts as 
described in 3.1.1. To generate rat engineered heart muscle (rEHM), all materials 
required were pre-chilled to 4°C and all steps were performed on ice. rEHMs were 
prepared from mixtures of collagen type I (rat tail, self-made), a basement membrane 
protein mixture (Matrigel™, BD), concentrated serum-containing culture medium (2x 
DMEM, pH adjusted to 7.4) and neonatal rat heart cells in EHM culture medium (see 
2.6) as shown in Table 19. The master mix volumes are adjusted to account for 
volume loss (≈15%) due to a viscous EHM mixture. EHMs were cast into custom-
made circular moulds (Figure 8) and allowed to solidify for 1h in a humidified 
incubator at 37°C and 5% CO2.  
 
 
Table 19: Composition of rEHM master mix 
Master mix components Volume [µL] 
Collagen (3.81 mg/mL), 0.8 mg/rEHM 283 
2x DMEM 283 
0.1 N NaOH 46 
Matrigel™ 207 
Total cell number (11.5 · 106), 2.5 · 106/rEHM 1251 
Total volume of master mix 2070 





Figure 8: Custom-made circular moulds for construction of rEHM. 
(A) Technical drawing of custom-made circular moulds for construction of two rEHMs with 
900 µL volume [178], (B) Mould with two consolidated rEHMs on culture day eight and 
magnified view of single mould. 
After gelation, 7 mL EHM culture medium were added to the casting mould. Medium 
was changed the next day and then every second day thereafter. On culture day 
eight, rEHMs were subjected to dynamic mechanical stretch at 1 Hz for 24 h, then at 
2 Hz for another six days. During this phase, rEHMs were treated with ROCK 




3.1.16 Generation of engineered heart muscle from hES2-wt CM and NHCF-V 
(hEHM) 
NHCF-V and hES2-wt CM were cultured and dissociated as described in 3.1.5 and 
3.1.6, respectively. However, for NHCF-V the enzymatic reaction was also stopped 
by adding three volumes of CM basal medium. The required number of hES2 wt CM 
and NHCF-V were combined, centrifuged at 300 g for 5 min at RT and the cells 




For construction of engineered heart muscle from human cells (hEHM), all materials 
required were pre-chilled and all steps performed on ice. Bovine collagen type I 
(Collagen Solutions, UK) and concentrated culture medium (2x RPMI, pH adjusted to 
7.4) were mixed with hES2 wt CM and NHCF-V in CM basal medium as shown in 
Table 20. The master mix volumes are adjusted to account for volume loss (≈17%) 
due to a viscous EHM mixture. 
 
Table 20: Composition of hEHM master mix 
Master mix components Volume [µL] 
Collagen (6.9 mg/mL), 0.4 mg/hEHM 271 
2x RPMI 271 
0.1 N NaOH 53 
Total cell number (4 · 106 hES2 wt CM + 2 · 106 NHCF-V), in total 
1.25 · 106/hEHM 
1506 
Total volume of master mix 2101 
Number of hEHM (450 µL/hEHM) 4 
 
The hEHM master mix was cast into custom-made circular moulds (Figure 9) and 
permitted to gel for 1h in a humidified incubator at 37°C and 5% CO2.  
 
Figure 9: Custom-made circular moulds for construction of hEHM. 
(A) Technical drawing of custom-made circular moulds for construction of 4 hEHMs with 
450 µL volume [178], (B) Mould with four consolidated hEHMs on culture day three and 
magnified view of single mould. 
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After gelation, 6 mL SFMM containing TGF1 was added to each mould. Medium 
was replenished with fresh SFMM containing TGF1 the next day. On culture day 
three, hEHMs were transferred to custom-made silicone dynamic stretchers (Sylgard 
184, Dow Corning) and SFMM medium without TGF1. During this phase, hEHMs 
were treated with ROCK inhibitor H1152P (3 µM). Medium was changed every 
second day and hEHMs were cultured until day 28. 
 
 
3.1.17 Generation of engineered connective tissue from NRCF (rECT) and 
NHCF-V (hECT) 
NRCF and NHCF-V were cultured as described in 3.1.3 and 3.1.5, respectively. To 
generate engineered connective tissue from NRCF (rECT) and engineered 
connective tissue from NHCF-V (hECT), all materials required were pre-chilled and 
all steps performed on ice. rECTs were prepared by mixing collagen type I (rat tail, 
self-made) and 2x DMEM with NRCF in NRCF growth medium according to Table 
21.  
 
Table 21: Composition of rECT master mix 
Master mix components Volume [µL] 
Collagen (rat tail, 3.81 mg/mL), 1.2 mg/rECT 725 
2x DMEM 725 
0.1 N NaOH 118 
Total cell number (3.91 · 106), 1.7 · 106/rECT 502 
Total volume of master mix 2070 
Number of rECT (900 µL/rECT) 2 
 
rECTs were cast into custom-made circular moulds (rat scale, see Figure 8) and 
allowed to gel for 1h in a humidified incubator at 37°C and 5% CO2.  
 
hECTs were prepared by mixing collagen type I (bovine) and 2x DMEM with NHCF-V 
in FGM3 according to Table 22. The pH of both mixtures was titrated to 7.4. 
Typically, rECTs and hECTs were prepared with an individual volume of 900 µL/rECT 
and 450 µL/hECT. 
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Table 22: Composition of hECT master mix 
Master mix components Volume [µL] 
Collagen (bovine, 6.9 mg/mL), 0.6 mg/hECT 400 
2x DMEM 400 
0.1 N NaOH 71 
Total cell number (3.45 · 106), 0.75 · 106/rECT 1200 
Total volume of master mix 2071 
Number of hECT (450 µL/hECT) 4 
 
Similar to rECTs, hECTs were cast into custom-made circular moulds (human scale, 
see Figure 9) and allowed to gel for 1h in a humidified incubator at 37°C and 5% 
CO2. Inhibitors and growth factors were directly added to the rECT or hECT master 
mix and also into the NRCF growth medium or FGM3. Concentrations of the 
inhibitors and growth factors used in the different experiments are outlined in Table 
23. 
 
Table 23: Concentration of inhibitors and growth factors used in rECT and hECT 
models 
Reagent Concentration 
Fasudil 10 µM 
H1152P 3 µM 
MMP408 10 µM 
TGFβ1 5 ng/mL 
 
After condensation, 7 mL NRCF growth medium or FGM3 were added to the casting 




3.1.18 Isometric force measurements of rEHMs and hEHMs 
EHM functionality was assessed by isometric force measurements in organ baths 
containing oxygenated Tyrode’s solution at 37°C (Figure 10) as described previously 





Figure 10: Isometric force measurement set-up 
(A) Set-up for isometric force measurements showing eight organ baths, (B) Magnified view 
of an organ bath, (C) hEHM during isometric force measurement in an organ bath. 
Prior to force measurements, the force transducers were calibrated with a 50 mg 
weight. rEHMs were stretched by stepwise length adjustment (125 µm) at 2 Hz 
electrical field stimulation in the presence of 1 mmol/L extracellular calcium until the 
length at which maximum force was generated (Lmax) was reached.  
 
hEHMs were stretched by stepwise length adjustment (62.5 µm) at 1.5 Hz electrical 
field stimulation in the presence of 1.8 mmol/L extracellular calcium. Contractile force 
of EHMs was measured under increasing extracellular calcium (0.2 - 2.4 mmol/L for 
rEHMs and 0.2 - 4 mmol/L for hEHMs). 
 
 
3.1.19 Destructive tensile strength measurement 
Destructive tensile strength of engineered tissues was performed using an RSA-G2 
rheometer (TA Instruments, see Figure 11A) to assess the viscoelastic properties of 





Figure 11: Experimental set-up for destructive tensile strength measurement of ECT 
and EHM. 
(A) Rheometer RSA-G2. (B) Tissues were fixed between two hooks and (C) measured in a 
controlled environment of 37°C in DPBS. 
Before the measurement was started, the transducer element of the rheometer was 
reset to zero. Engineered tissues were transferred to a bath containing DPBS at 
37°C and suspended between two custom-made hooks (see Figure 11B and C). 
Tissues were then stretched with a constant linear rate of 0.05 mm/s for rat tissues 
and 0.03 mm/s for human tissues till the point of rupture. 
 
 
3.1.20 Dissociation of cells from engineered tissues 
Engineered tissues were dissociated by incubation in 500 µL (rat tissues) or 250 µL 
(human tissues) collagenase I solution (see 2.6) for 2 h at 37°C. The supernatant 
was transferred to a tube, tissues were washed once with PBS containing 5% FBS 
and incubated in the same volume of digestion medium (see 2.6) for 45 min at RT to 
achieve complete dissociation. The remaining tissue was mechanically dissociated 
by gentle pipetting and the supernatant transferred to the tube. Cells were 
centrifuged for 5 min at 300 g and 4°C, resuspended in PBS containing 5% FBS, 
counted as described before using the CASY TT system and subsequently fixed with 
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3.2 Histological methods 
3.2.1 Immunofluorescence and staining of the actin cytoskeleton and the 
nucleus in cells 
Cells were washed with DPBS and fixed with 4% Paraformaldehyde (PFA) in DPBS 
for 15 min. They were then washed three times with DPBS, permeabilized with 
0.02% Triton X-100 in DPBS for 3 min and again washed three times prior to 
blocking in 1x Roti-Block (in DBPS) for 1 h at RT. After three more washes with 
DBPS, cells were incubated with the appropriate primary protein-specific antibody in 
DBPS overnight at 4°C (see 2.9.1). 
 
The next day, cells were washed three times with DBPS, followed by incubation with 
fluorochrome-conjugated secondary antibodies in DBPS for 1 h at RT in the dark 
(see 2.9.3). Additionally, staining of the actin cytoskeleton with TRITC-labelled 
phalloidin and of the cell nucleus with DAPI (1 µg/mL) in DBPS was performed for 1 h 
at RT in the dark. Finally, cells were washed twice with DBPS and the samples were 
imaged using an inverted fluorescence microscope (Olympus) with a CM 10 T 
camera (Olympus) and 10x-60x objectives. CellM Software (Olympus) was used for 
image processing, including adjustments for brightness and contrast. 
 
 
3.2.2 Quantitative evaluation of focal adhesions (FAs) in NRCF 
FAs were immunostained for vinculin, a membrane-cytoskeletal protein found in FAs. 
In order to analyse the quantity and size of FAs in NRCF, image processing was 
carried out using ImageJ and an optimized analysis protocol published by Horzum et 







In brief, the raw images were processed as follows: 
I. Subtract background: Sliding paraboloid option with rolling ball radius set to 
2 pixels 
II. CLAHE (Contrast Limited Adaptive Histogram Equalization): block size=19, 
histogram bins=256, slope=6, no mask and fast [181] 
III. Mathematical exponential (Exp) 
IV. Brightness & Contrast: Automatically adjusted 
V. Threshold: default method; pixel values: 255 (white) and 3 (black) 
VI. Analyse particles: size=0.001-50 µm2 and circularity=0.00-1.00 
 
 
Figure 12: Graphical summary of the quantitative evaluation of focal adhesions in 
NRCF. 
From the raw image, background was subtracted. Afterwards, local contrast of the image 
was enhanced using CLAHE and mathematical exponential was applied to further minimize 
the background. Brightness and contrast were adjusted and the image converted to a binary 
image using the threshold command. Finally, analyse particles command was used to count 
and measure FAs. 
 
Subtract  









3.2.3 Flow cytometry cell cycle analysis 
Analysis of the replication state of a cell population can be achieved by fluorescently 
labelling and quantifying DNA content. Cells that are in S phase will have more DNA 
than quiescent and G1 cells. Accordingly, they proportionally uptake more dye and 
thus fluoresce brighter. Cells in G2 or M phase have two copies of DNA and will be 
approximately twice as bright as cells in G0/G1 phase. 
 
Engineered tissues were dissociated according to 3.1.20 and resultant cells were 
fixed in ice-cold 70% ethanol for 30 min at 4°C. Samples can be left at this step for 
several weeks. Cells were then washed twice in phosphate-citrate buffer. To ensure 
that only DNA is stained, cells were subsequently treated with 50 µL of 100 µg/mL 
RNase. To stain the DNA, cells were incubated in 300 µL of 50 µg/mL propidium 
iodide (PI) for 30 min at 37°C, centrifuged (300 g, 5 min, 4°C), resuspended in 
500 µL DPBS and then analysed by flow cytometry. 
 
Cell debris was excluded by measuring for forward scatter (FS) and side scatter 
(SS). Pulse processing was used to exclude aggregates by plotting pulse area (FL2-
A) vs. pulse width (FL2-W). Subsequently, cells in G0/G1, S, and G2/M phase were 
identified using a histogram of the pulse area (FL2-A). 
 
 
3.3 Protein biochemical methods 
3.3.1 Isolation of proteins from cultured cells 
To obtain protein from NRCF, cells were washed with cold DBPS and scraped off 
using an adequate volume of cold GST-Fish lysis buffer. Samples were centrifuged 
at 13,000 g, 4°C for 10 min, snap frozen in liquid nitrogen and stored at -80°C.  
 
 
3.3.2 Determination of protein concentration (Bradford assay) 
A modified Bradford colorimetric protein assay was performed to determine the 
concentration of protein lysates [182]. A series of bovine serum albumin (BSA) 
standards (0 - 2.0 µg BSA) and protein samples were prepared in 50 µL ddH2O and 
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pipetted into 96-well microtiter plates in triplicate. 200 µL 1x Roti Nanoquant solution 
was added to each well. The formation of the protein-dye complex was detected at 
595 nm using a spectrophotometric microplate reader (FlexStation3). Protein 
concentration was calculated according to the obtained BSA standard curve. 
 
 
3.3.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was used for separation of protein mixtures according to their size. For 
efficient separation of proteins, a 5% stacking gel and, according to the size of 
proteins to be detected, a resolving gel with an acrylamide/bisacrylamide 
concentration of 6-15% was used (see Table 24). 
 
Table 24: Master mix of stacking and resolving gels used for SDS-PAGE 















ddH2O 2.8 mL 2.3 mL 1.9 mL 1.6 mL 1.1 mL 
1.0 M Tris/HCl, pH 
6.8 
0.38 mL - - - - 
1.5 M Tris/HCl, pH 
8.8 
- 1.3 mL 1.3 mL 1.3 mL 1.3 mL 
Acrylamide/bisacryla
mide mix 
1.3 mL 1.3 mL 1.7 mL 2.0 mL 2.5 mL 
10% SDS 0.03 mL 0.05 mL 0.05 mL 0.05 mL 0.05 mL 
10% APS 0.03 mL 0.05 mL 0.05 mL 0.05 mL 0.05 mL 
TEMED 0.003 mL 0.003 mL 0.002 mL 0.002 mL 0.002 mL 
Volume 3 mL 5 mL 5 mL 5 mL 5 mL 
 
Whole cell lysates were mixed with 4x SDS loading buffer without glycerol on the 
basis of the calculated protein concentrations and incubated at 95°C for 5 min. 
Protein samples were loaded and separated at 200 V in 1x SDS running buffer until 




3.3.4 Western immunoblotting 
Following SDS-PAGE, proteins were electrotransferred to nitrocellulose membranes. 
For this, the gel and membrane were sandwiched between filter paper and immersed 
in ice-cold immunoblotting buffer for 1 h at 100 V. The immunoblot setup was 
additionally cooled with ice. To visualise successful protein transfer, membranes 
were stained with PonceauS solution for 3 min. They were then washed with TBST 
buffer until the PonceauS stain was no longer visible. Membranes were blocked with 
1x Roti-Block in ddH2O for 1 h at RT. 
 
Membranes were incubated with primary antibodies against the desired protein of 
interest diluted in TBST buffer and incubated overnight at 4°C (see 2.9.1). 
Membranes were washed thrice for 10 min in TBST buffer and probed with 
appropriate horseradish peroxidase-conjugated secondary antibodies for 1 h at RT 
(see 2.9.2). After a final round of washing with TBST buffer, protein signals were 
visualised by enhanced chemiluminescence (Lumi-LightPLUS or Super Signal West 
Femto) in a VersaDoc imaging system (Bio-Rad Laboratories). Quantification of the 
signals was performed using ImageLab 5.1 analysis software (Bio-Rad Laboratories). 
 
 
3.3.5 Identification of potential ROCK targets using PamGene’s kinase activity 
profiling technology 
The PamGene kinase activity profiling system can be used to identify new targets for 
kinases, in this case ROCK1 and ROCK2. In this study, PamChip arrays were 
utilised, which consist of 140 Ser/Thr containing peptides and 4 positive 
phosphorylated control peptides immobilized on the microarray. Each peptide 
represents a 15 amino acid sequence, of which 13 residues were derived from 
phosphorylation sites in various human proteins.  
 
Measurements of peptide phosphorylation by kinases is accomplished by incubating 
the purified kinase on the microarray and detection using a mixture of primary and 
fluorescently labelled secondary antibodies. Images of the fluorescence intensity 





Figure 13: Schematic drawing of the PamGene kinase activity profiling system. 
The PamChip arrays consist of 144 peptides which are spotted on a porous membrane. 
Peptide phosphorylation by kinases is detected using a mixture of primary and fluorescently 
labelled secondary antibodies [183]. 
Phosphorylation of peptides was measured according to the kinase activity profiling 
protocol supplied by the manufacturer. Briefly, the PamChip arrays were blocked with 
2% BSA, the assay master mix was prepared on ice as shown in Table 25, and 
applied to the array. After termination of the run, the detection master mix was 
prepared on ice as shown in Table 26 and loaded onto the array. 
 
Data analysis consisting of image quantification, quality control and statistical 
analyses was kindly performed by Dr. Hanibal Bohnenberger (Institute of Pathology, 




Table 25: Composition of kinase activity profiling assay master mix 
Master mix components Amount 
10x PK buffer 4 µL 
100x BSA solution 0.4 µL 
Sample (purified kinase) 0.1-20 ng 
4 mM ATP solution 4 µL 
Water To a final volume of 40  µL 
 
Table 26: Composition of kinase activity profiling detection master mix 
Master mix components Amount 
10x Ab buffer 3 µL 
STK antibody mix 0.23 µL 
STK antibody FITC-labelled 0.08 µL 
Water 26.69 µL 
 
 
3.3.6 In vitro kinase assay 
To verify whether ROCK1 and ROCK2 can phosphorylate p21 and CDK7 in an in 
vitro kinase assay, recombinant human ROCK1 or ROCK2 (SignalChem) was 
incubated with the target substrate (recombinant p21 or recombinant inactive CDK7, 
SignalChem) in kinase buffer in the presence of adenosine 5’-triphosphate (ATP) and 
[γ-32P]ATP (see Table 27) at 30°C for 30 min.  
 
Subsequently, 10 µL 4x SDS loading buffer with glycerol were added and the 
samples incubated at 95°C for 5 min. Samples were loaded on a 4-15% gradient gel 
and separated at 100 V in 1x SDS running buffer until the dye front ran from the gel. 
The gel was then fixed in fixing buffer for 30 min at RT, dried for 2 h at 70°C and 
protein phosphorylation was analysed by autoradiography of the dried gel. 
 
Table 27: Master mix for kinase assay 
Master mix components Amount 
2x Kinase buffer 15 µL 
ATP 0.3 µL 
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[γ-32P]ATP 0.1 μCi/μL 
Substrate (p21, CDK7) 2 µg 
Kinase (ROCK1, ROCK2) 100 ng 
ddH2O ad 30 µL 
 
 
3.3.7 Co-Immunoprecipitation (Co-IP) 
HEK293A cells were co-transfected as described in 3.1.10. After 24 hours, cells were 
washed with DPBS and 1 mL of IP lysis buffer was added to each dish. After 10 min 
of incubation on ice, cells were scraped and lysates centrifuged at 13,000 rpm at 4°C 
for 10 min. The supernatant was transferred to a fresh microtube, and 150 µL of the 
supernatant was separated to check total protein levels by immunoblotting.  
 
α-myc agarose beads were washed three times with IP lysis buffer. Cell lysates were 
incubated with 10 µL of α-myc agarose beads per sample for 2 h at 4°C with rotation. 
Subsequently, beads were washed three times with IP lysis buffer and 
immunocomplexes were dissociated from the beads by boiling with 2x SDS loading 




3.4 Molecular biological methods 
3.4.1 DNA isolation 
Small scale preparation of DNA was performed for quality control of the lentiviral 
plasmids containing the respective shRNAs to knockdown ROCK1 and both kinases. 
This was performed using the Exprep Plasmid SV mini kit (GeneAll) following 
recommended manufacturer instructions. 
 
Large scale preparation of DNA was performed to isolate the lentiviral plasmids 
containing the respective shRNAs to knockdown ROCK1 and ROCK2 for transfection 
into Tsa201 cells. For this, XChange Plasmid Maxi Kit (Peqlab) was used and 
protocol followed according to the manufacturer’s instructions. 
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The concentration and purity of isolated nucleic acids were measured using 
spectrophotometric quantification with the NanodropTM ND-1000 system. DNA 
concentration was calculated as follows: 
 
 
    A260: Absorbance at 260 nm 
    A260 of 1.0 = 50µg/ml pure dsDNA 
 
To evaluate DNA purity, the ratio of the absorbance at 260 nm divided by the reading 
at 280 nm was calculated. Good quality DNA will have an A260/A280 ratio of 1.7–2.0. 
Samples were stored at -20°C until required. 
 
 
3.4.2 Restriction digest 
For quality control of lentiviral plasmids, plasmid DNA was digested using BamHI and 
NdeI (NEB). 10 U of the respective restriction enzyme was added to 1x reaction 
buffer and 1 μg of vector DNA. Water was added to a final volume of 30 μL and the 
reaction mix was incubated for 4 h, or overnight at 37°C. Restriction enzymes were 
inactivated at 65°C for 20 min. 
 
 
3.4.3 DNA agarose gel electrophoresis 
DNA agarose gel electrophoresis was used to separate and analyse DNA fragments 
based on their size and charge. To prepare a 1% agarose gel, 1 g agarose was 
mixed with 100 mL of 1x TAE buffer. After heating the mixture to melt the agarose 
and cooling it down to 65°C, 0.5 µg/µL of ethidium bromide was added and the 
solution was poured onto the gel support. DNA samples were separated in 1x TAE 
buffer at 120 V. DNA bands were visualized at 312 nm in the GelDoc XR imaging 







3.4.4 RNA isolation from cells and engineered tissues 
Isolation of total RNA from cultured cells was performed using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions.  
 
For isolation of RNA from engineered tissues, the phenol-chloroform method was 
used. For this, 1 mL TriFast(peqGOLD) was added per tissue and incubated at 4°C 
overnight to dissolve the collagen hydrogel. The following day, remaining pieces of 
tissue were mechanically dissociated by vigorous pipetting and subsequent RNA 
isolation as per the manufacturer’s protocol. To further clean up the RNA, the clean-
up protocol of the RNeasy Mini Kit was used.  
 
Isolated RNA was eluted in the appropriate amount of RNase-free H2O. 
Concentration and purity of isolated RNA was measured using spectrophotometric 
quantification by the NanodropTM ND-1000 system. RNA concentration was 
calculated as follows: 
 
 
     A260: Absorbance at 260 nm 
    A260 of 1.0 = 40µg/ml pure ssRNA 
 




3.4.5 Formaldehyde agarose gel electrophoresis 
Formaldehyde agarose gel electrophoresis was performed to verify the integrity of 
RNA samples. To prepare a 1.2% formaldehyde gel, 1.2 g agarose were mixed with 
10 mL of 10x FA buffer and 100 mL of RNase-free H2O. After heating the mixture to 
melt the agarose and cooling down to 65°C, 1.8 mL of 37% formaldehyde and 





Prior to performing the electrophoresis, the gel was equilibrated in 1x FA gel running 
buffer for at least 30 min. For RNA sample preparation, 1 volume of 5x RNA loading 
buffer was mixed to 4 volumes of RNA sample. Before sample loading into the 
equilibrated gel, samples were incubated for 3-5 min at 65°C and then chilled on ice. 
RNA samples were separated in 1x FA gel running buffer at 120 V for at least 




3.4.6 cDNA synthesis 
Isolated RNA (see 3.4.4) was used to transcribe RNA into copyDNA (cDNA) using 
the RevertAid™ First Strand cDNA Synthesis kit (Fermentas) according to the 
manufacturer’s instructions. All steps were performed on ice. The composition of the 
cDNA master mix and the reverse transcription protocol are outlined in Table 28. The 
cDNA samples were stored at -80°C. 
 
Table 28: Composition of cDNA master mix and reverse transcription protocol 
Master mix components Amount 
Template RNA  150 ng 
Oligo (dT)18 primer 1 µL 
 Incubate at 65°C for 5 min 
5x reaction buffer 4 µL 
RiboLock RNase inhibitor (20 U/µL) 1 µL 
10 mM dNTP mix 2 µL 
RevertAid M-MuLV RT (200 U/µL) 1 µL 
 incubate at 42°C for 60 min, terminate reaction at 
70°C for 5 min 
 
 
3.4.7 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Quantitative real-time PCR was used to simultaneously amplify and semi-quantify 
cDNA. Non-specific fluorescent dyes, such as the EvaGreen® dye (Solis Biodyne) 
The fluorescence measured after each elongation cycle is thus proportional to the 
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amount of cDNA in the reaction. The normalized target gene expression level was 




All measurements were performed in quadruplicates. The final reaction was mixed as 
shown in Table 29. The qRT-PCR program is shown in Table 30. The list of the qRT-
PCR primer sets can be found in 2.11.  
 
Table 29: Master mix for qRT-PCR per 1 µL cDNA 
Reagent Volume 
cDNA (1:40) 1 µL 
Primer for (10 pmol/µL) 1 µL 
Primer rev (10 pmol/µL) 1 µL 
Template DNA /Standard DNA (1:20) 1 µL 
RNase-free water 13 µL 
5x EvaGreen® dye 4 µL 
 
 
Table 30: qRT-PCR cycling program 
Cycle Temperature Time Number of Cycles 
Initial denaturation 95°C 15 min 1 
Denaturation 95°C 15 s  
40 Annealing 60°C 20 s 
Elongation 72°C 40 s 
Dissociation curve 95°C 15 s  
1 60°C 15 s 




Experimental data are presented as means ±SEM. Data was analysed by 1-way or 2-
way ANOVA, with Bonferroni’s post hoc multiple comparison test, or by unpaired t-
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test assuming normal distribution. Statistical calculations were performed utilising 




4.1 ROCK1 and ROCK2 regulate cardiac fibroblast morphology and adhesion 
4.1.1 Selective knockdown of ROCK1 and ROCK2 
In order to study the role of ROCK1 and ROCK2 in cardiac fibroblasts further, 




Figure 14: Validation of isoform-selective knockdown of ROCK1 and ROCK2 in NRCF. 
(A) qPCR analysis of ROCK1 and ROCK2 mRNA in siROCK1 and siROCK2 compared to 
siControl NRCF are shown (means ±SEM, n=4, *p<0.05, values were normalized to the 
mean of glucuronidase , PBGD, and vimentin). (B) Representative immunoblots of ROCK1, 
ROCK2, and α-tubulin in siControl, siROCK1, and siROCK2 NRCF. (C) Quantification of the 
relative change in ROCK1 and ROCK2 protein expression in siROCK1 and siROCK2 















As can be seen in Figure 14A, a selective downregulation of ROCK1 mRNA by about 
50% and ROCK2 mRNA by about 60% was achieved. Additionally, ROCK1 protein 
was reduced by 70% and ROCK2 protein by 60% (Figure 14B, C). NRCF transfected 




4.1.2 Downregulation and inhibition of ROCK1 and ROCK2 changes NRCF 
morphology 
As ROCK1 and ROCK2 are major regulators of the cytoskeleton in various cell types, 
the effect of ROCKs on NRCF morphology was evaluated. In Figure 15A 
representative fluorescent images of siControl, siROCK1, and siROCK2 NRCF are 
depicted. The downregulation of ROCK1 and ROCK2 was associated with changes 
in cardiac fibroblast morphology, as the area of NRCF was significantly increased 
1.6-fold in siROCK1 and 2-fold in siROCK2 NRCF when the cells were attached 
(Figure 15B). Additionally, NRCF were treated with the non-selective ROCK inhibitors 
Fasudil and H1152P to inhibit ROCK activity. Also here, cell area was significantly 






Figure 15: Evaluation of cell morphological changes. 
(A) Fluorescence staining of f-actin with phalloidin (grey) and cell nuclei with DAPI (blue) in 
siControl, siROCK1, and siROCK2 NRCF. Relative cell area of (B) siROCK1 and siROCK2 
compared to siControl NRCF (means ±SEM, n=3-5, *p<0.05, >50 cells each) and (C) 
Fasudil- (10 µM) and H1152P-treated (3 µM) compared to control NRCF is shown 
(means ±SEM, n=3, *p<0.05, >50 cells each). 
In addition, the organisation and formation of the actin cytoskeleton was found to be 
disturbed in NRCF with a downregulation of ROCK1 and of both kinases. Higher 
order actin structures, including geodesic domes and partially geodesic structures 
were reduced in shROCK1 and shROCK1/2 cells, whereas star-shaped actin 
bundles and cortical actin structures were increasingly present (Figure 16A, B). The 
observed change in NRCF morphology was most prominent in NRCF with a 
downregulation of ROCKs which was achieved by lentiviral delivery of shRNAs. 
Geodesic dome actin structures were highly present in shscr cells (20% of all cells), 
whereas in siRNA transfected or control NRCF only 2.5% or 5% of all cells showed 
geodesic structures (Figure 16C). This suggests that the high number of geodesic 




Figure 16: Analysis of geodesic f-actin structures in NRCF. 
(A) Fluorescence staining of f-actin structures in NRCF showing geodesic, mixed, and non-
geodesic cells. (B) The percentage of geodesic, mixed, and non-geodesic NRCF in shscr, 
shROCK1, and shROCK1/2 NRCF is shown. (C) Comparison of number of geodesic NRCF 
in lentivirus-mediated ROCK knockdown, siRNA-mediated ROCK knockdown, and NRCF 
treated with ROCK inhibitors Fasudil (10 µM) and H1152P (3 µM; means ±SEM, n=3, 
*p<0.05, >50 cells each). 
Although a strong effect on NRCF morphology after downregulation of ROCKs could 
be seen, no change in the expression of cytoskeletal proteins, as for example β-actin, 
α-tubulin or αSMA, an important myofibroblast marker, could be detected by 

















Figure 17: Expression of cytoskeletal proteins in ROCK knockdown NRCF. 
Representative immunoblots of ROCK1, ROCK2, vinculin, α-tubulin, α-sm-actin, and -actin 
in shROCK1 and shROCK1/2 compared to shscr, and in siROCK1 and siROCK2 compared 
to siControl NRCF are shown. 
4.1.3 ROCK knockdown reduces adhesion velocity and alters the size and 
amount of focal adhesion sites in NRCF 
To evaluate whether the morphological changes had an impact on adhesion of 
NRCF, a static adhesion assay was performed. The knockdown ROCK1 or ROCK2 
significantly increased adhesion velocity to a normal cell culture surface (Figure 18A, 
left); however, no difference could be seen for adhesion to a collagen-coated surface 
(Figure 18A, right). Double knockdown of ROCK1 and ROCK2 did not have a 




Figure 18: Analysis of adhesion velocity of ROCK knockdown NRCF. 
Adhesion assay on a plastic tissue culture surface (left graphs) and on collagen (right 
graphs) over the time course of 1 h. (A) Adherent siROCK1 and siROCK2 compared to 
siControl NRCF and (B) adherent shROCK1 and shROCK1/2 compared to shscr NRCF are 
shown (means ±SEM, n=3-5, *p<0.05, % of total cells). 
To evaluate this further, the number and size of focal adhesions (FAs) in siROCK1 
and siROCK2 was compared to siControl NRCF using quantitative analysis of 
images with vinculin immunostaining. A representative processed image can be seen 
in Figure 19A. In accordance to the results of the static adhesion assay, the number 
of focal adhesion sites per cell was significantly increased by 163% in siROCK1 and 
by 156% in siROCK2 NRCF compared to siControl (Figure 19B). Interestingly, the 
average size of a single FA in siROCK1 and siControl NRCF was the same, whereas 
siROCK2 NRCF formed 38% smaller FAs (Figure 19C). In addition, the area of all 
FAs in one cell was significantly increased by 230% in siROCK1, and by 60% in 












Figure 19: Evaluation of focal adhesion number and size in ROCK1 and ROCK2 
knockdown NRCF. 
(A) Representative image of a cell following image processing by ImageJ with detected FAs 
shown in yellow. Analysis of (B) total number of FAs identified per cell, (C) average size of a 
single FA, and (D) area of all FAs in one cell (means ±SEM, n=3, *p<0.05, 10 cells each). 
4.2 ROCK1 and ROCK2 regulate cardiac fibroblast migration 
4.2.1 Knockdown and inhibition of ROCK1 and ROCK2 have contrasting 
effects on the migratory behaviour of NRCF on a plane surface 
In order to evaluate whether the changes in cardiac fibroblast morphology and 
adhesion also impact the migration behaviour of NRCF with a downregulation of 
ROCK1 and ROCK2, live cell experiments over a time course of 24 h were 
performed. The data shows that the knockdown of ROCK1 and ROCK2 decreased 
velocity of migration by 60% and 70%, respectively (Figure 20A). Absolute migrated 
distance of NRCF was reduced by 55% in siROCK1 NRCF and by 70% in siROCK2 
NRCF compared to siControl (Figure 20B). Directionality of migration was unchanged 
(Figure 20C). Analysis of the migrated distance of siROCK1 and siROCK2 NRCF per 
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hour showed, that cells migrated approximately the same distance each hour proving 




Figure 20: Analysis of migration of siRNA-mediated ROCK knockdown NRCF on a 
planar surface. 
Migration of ROCK knockdown NRCF on a planar surface over the course of 24 h. Bar graph 
summary of (A) average migration velocity, (B) directionality of migration, and (C) absolute 
migrated distance of siROCK1 and siROCK2 compared to siControl NRCF shown (means 
±SEM, n=6, *p<0.05, >15 cells each). (D) Migrated distance of siROCK1 and siROCK2 
NRCF per hour compared to siControl NRCF (means ±SEM, n=3, *p<0.05, >15 cells each). 
Interestingly, knockdown of both kinases, as well as inhibition of ROCK activity using 
H1152P had a contrasting effect on the migratory behaviour of NRCF. Velocity of 
migration and absolute migrated distance of NRCF were both significantly increased 
by about 80% in shROCK1/2 NRCF compared to shscr. An effect of the lentivirus on 
NRCF can be excluded, as a trend towards a decreased migration velocity and 
distance could also be observed in shROCK1 NRCF (Figure 21A, B). Likewise, 
treatment with 3 µM H1152P resulted in an increase in migration velocity and 











migratory behaviour (Figure 21D, E). Moreover, both downregulation of ROCK1 and 
ROCK2, as well as inhibition of ROCK activity did not change directionality of 
migration (Figure 21C, F). 
 
 
Figure 21: Evaluation of migration of lentivirus-mediated ROCK knockdown NRCF and 
NRCF treated with ROCK inhibitor. 
Migration of NRCF on a planar surface over the course of 24 h. Bar graph summary of (A) 
average migration velocity, (B) absolute migrated distance, and (C) directionality of migration 
of shROCK1 and shROCK1/2 compared to shscr NRCF is shown (means ±SEM, n=3, 
*p<0.05, >15 cells each). Bar graph summary of (D) average migration velocity, (E) absolute 
migrated distance, and (F) directionality of migration of NRCF treated with ROCK inhibitor 
H1152P (300 nM and 3 µM) compared to control NRCF is shown (means ±SEM, n=3-4, 
*p<0.05, >15 cells each). 
In Figure 22, representative bright field images of the differently treated NRCF during 
the live cell experiment are shown. As can be seen in Figure 22B and C, shROCK1/2 
NRCF, as well as NRCF treated with 3 µM H1152P showed a highly collapsed cell 
shape, which stayed constant over time. This could not be observed in NRCF with a 




Figure 22: Bright-field images of ROCK knockdown NRCF and NRCF treated with 
ROCK inhibitor H1152P during migration. 
Representative bright-field images of differently treated NRCF during migration on a planar 
surface. (A) siControl, siROCK1, and siROCK2 NRCF, (B) shscr, shROCK1, and 
shROCK1/2 NRCF, and (C) control NRCF and those treated with either 300 nM or 3 µM 
H1152P. (D) Representative bright field images of H1152P-treated and control NRCF during 
the live cell experiment are shown. 
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4.2.2 Downregulation of ROCK1 and ROCK2 impairs migration of NRCF in a 
transwell assay 
In the next step, the migration of NRCF through pores, as assessed by a transwell 
migration assay, was analysed. For this, NRCF were seeded on a porous membrane 
and the number of cells located inside the pores after 24 h was evaluated (Figure 
23A). The experiments were performed with low serum (1%) or with 10% serum as a 
migration stimulus. NRCF with a knockdown of both ROCK1 and ROCK2 showed a 
significantly reduced migratory performance of about 50% under low and high serum 
conditions when compared to shscr NRCF. Interestingly, shROCK1 cells showed 
only a trend towards a reduced migration under no serum conditions, but not under 
high serum conditions (Figure 23B). 
 
 
Figure 23: Analysis of transwell migration through a porous membrane. 
Representative fluorescent image of a membrane with NRCF inside a porous membrane 
(pore size 8 µm) assessed by Hoechst staining (NRCF marked by red arrows). (B) 
Quantitative analysis of shROCK1 and shROCK1/2 compared to shscr NRCF migrating 
through a porous membrane in the presence of low serum (1%) and high serum (10%) is 
shown. The relative number of cells is given (means ±SEM, n=7, *p<0.05). 
4.3 ROCK1 and ROCK2 activity is needed for cardiac fibroblast proliferation 
To further establish the important role of ROCK1 and ROCK2 in the fibroblast-
myofibroblast transition, the proliferative capacity of cardiac fibroblasts after ROCK 








analysed. Interestingly, only the knockdown of both kinases (see Figure 6), as well as 
the general inhibition of ROCK activity by H1152P (Figure 24B) stopped proliferation 
of NRCF, whereas downregulation of either ROCK1 or ROCK2 did not have an effect 
on proliferation capacity (Figure 24A). This suggests that proliferation of cardiac 




Figure 24: Analysis of proliferation of ROCK knockdown NRCF and NRCF treated with 
ROCK inhibitor. 
(A) Proliferation assay of siROCK1 and siROCK2 compared to siControl NRCF over the time 
course of six days (means ±SEM, n=5, measured in 4 technical replicates/experiment). (B) 
Proliferation assay of control NRCF treated with H1152P (3 µM) over a time course of 6 days 
(means ±SEM, n=4, measured in 4 technical replicates/experiment, * p<0.05). 
The cause for the diminished proliferation was investigated further and fluorescent 
analysis of NRCF revealed that H1152P-treated fibroblasts were mostly double-
nucleated (66% double-nucleated vs. 34% single-nucleated), whereas control cells 
displayed predominantly one nucleus (14% double-nucleated vs. 86% single-
nucleated; Figure 25B). Moreover, in live cell experiments it was shown that H1152P 
treatment led to a cytokinesis defect in NRCF. Rather than dividing into two daughter 
cells, H1152P-treated NRCF failed to divide, which resulted in a higher percentage of 
double-nucleated cells as compared to control (59% vs. 18% double-nucleated in 






Figure 25: Analysis of single- and double-nucleated NRCF after treatment with ROCK 
inhibitor H1152P. 
(A) Representative fluorescent stainings of f-actin by phalloidon (red) and cell nuclei by DAPI 
(blue) of control and NRCF treated with H1152P (3 µM). Double-nucleated cells are marked 
by a white arrow. (B) Bar graph summary showing the relative number of single- or double-



























n=3, >150 cells each, * p<0.05 vs. control). (C) NRCF were treated with H1152P (3 µM) and 
live cell imaging over the time course of 24 h was performed. Shown is the relative number of 
cells that divided into two single-nucleated daughter cells or that failed to divide resulting in a 
double-nucleated cell (means ±SEM, n=3, * p<0.05 vs. control). (D) Representative images 
of control and H1152P-treated NRCF undergoing cell division during live cell imaging are 
shown. (E) Bar graph summary showing the relative number of single- or double-nucleated 
shROCK1, shROCK1/2, and shscr NRCF (means ±SEM, n=3, >150 cells each, * p<0.05 vs. 
shscr). 
4.4 ROCK1 and ROCK2 influence the regulation and turnover of the ECM and 
viscoelastic properties in engineered connective tissues from rat and 
human cardiac fibroblasts 
4.4.1 Inhibition of ROCK activity impairs the consolidation of hECT and 
decreases hECT stiffness 
Another characteristic of myofibroblasts is their altered gene expression profile and 
increased secretory behaviour when compared to quiescent cardiac fibroblasts. In 
order to study the functional role of cardiac fibroblasts in a more physiological model 
than a 2D culture, engineered connective tissue (ECT) consisting of cardiac 
fibroblasts and collagen I as a hydrogel were used. In preliminary experiments, the 
influence of ROCK1 and ROCK2 signalling on ECT consisting of NRCF (rECT) was 
analysed (see 2.10). In the following experiment, this should also be demonstrated in 
the human model using human cardiac fibroblasts (NHCF-V). Therefore, we 
generated hECT from an initially liquid mixture composed of NHCF-V and collagen 
type I and treated them with the non-selective ROCK inhibitors Fasudil and H1152P. 
In Figure 26A, representative images of the hECT are depicted. Both Fasudil- and 
H1152P-treated hECT were less consolidated after five days in culture with an 
increase in cross-sectional area (CSA) of 45% in Fasudil- and of 120% in H1152P-





Figure 26: Treatment with ROCK inhibitors increased the cross-sectional area (CSA) of 
human engineered connective tissue (hECT). 
(A) Representative images of control, Fasudil- (10 µM) and H1152P-treated (3 µM) hECT 
composed of normal human cardiac fibroblasts from the ventricle (NHCF-V). (B) Differences 
in calculated CSA of the different hECT are shown (means ±SEM, n=5, *p<0.05 vs. control, 
values illustrate numbers of hECT measured).  
To define viscoelastic properties of the hECT, rheological destructive tensile strength 
measurement was performed. In Figure 27A, a typical stress-strain curve as a result 
of these measurements including important parameters is depicted. Representative 
stress-strain curves of control, Fasudil-, and H1152P-treated hECT can be seen in 










Figure 27: Stress-strain curves of rheological destructive tensile strength 
measurements. 
(A) Representative stress-strain curve of a cellular collagen hydrogel as a result of 
rheological destructive tensile strength measurement highlighting important parameters. (B) 
Representative stress-strain curves of control, Fasudil- (10 µM) and H1152P-treated (3 µM) 
hECT during a rheological destructive tensile strength measurement. 
Measurements revealed that stiffness of the hECT as defined by the Young’s 
modulus was significantly reduced by 30% in Fasudil- and by about 50% in H1152P-
treated tissues compared to control (Figure 28A). Moreover, ROCK inhibitor-treated 
tissues tolerated less maximal stress than control tissues (Figure 28B) with a 
decrease of 35% in Fasudil- and 55% in H1152P-treated hECT. In addition, more 
ultimate stress was needed until microfractures in the tissues occurred (Yield point), 
as the stress value at the yield point was decreased by 40% in Fasudil- and by 55% 
in H1152P-treated hECT (Figure 28C, left). Likewise, rupture of the tissue (Failure 
point) after ROCK inhibition occurred at a lower stress value compared to control, 
which was decreased by 30% in Fasudil- and by 50% in H1152P-treated hECT 
(Figure 28D, left). However, there was no significant difference found regarding strain 
values at the yield and failure point, meaning the ROCK inhibitor-treated hECT were 
torn apart the same length as control tissues when they experienced microfractures 
















Figure 28: Analysis of the viscoelastic properties of control, Fasudil-, and H1152P-
treated hECT. 
Changes in (A) the Young’s modulus, (B) maximum stress value, (C) stress (left) and strain 
value (right) at the yield point, and (D) stress (left) and strain value (right) at the failure point 
are depicted (means ±SEM, n=5, * p<0.05 vs. control, values illustrate numbers of hECT 
measured). 
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4.4.2 ROCK inhibition influences the cell cycle, but not proliferation of NRCF 
in rECT 
To evaluate changes that occur in response to ROCK inhibition in ECT further, the 
experiments were continued using ECT from NRCF (rECT) due to feasibility reasons. 
Re-isolation of NRCF by collagenase/accutase digestion of rECT revealed that the 
cell number in the ROCK inhibitor-treated rECT were the same as in control tissues, 
excluding that the observed changes were due to excessive cell proliferation or cell 
death as a reason for the observed decrease in tissue stiffness (Figure 29A).  
 
 
Figure 29: Flow cytometry cell cycle analysis of cells dissociated from control, 
Fasudil- and H1152P-treated rECT. 
NRCF were dissociated from rECT and DNA was stained with propidium iodide to analyse 
the replication state of the cell populations. (A) Bar graph summary of number of NRCF after 
dissociation from control, Fasudil-, and H1152P-treated rECT (means ±SEM, n=6). (B) Bar 
graph summary of cell populations in G0G1-, S-, and G2M-phase of NRCF dissociated from 
control, Fasudil-, and H1152P-treated rECT. (C) Number of single- and double-nucleated 
NRCF measured after dissociation from control, Fasudil-, and H1152P-treated rECT 







Interestingly, cell cycle analysis of re-isolated NRCF using propidium iodide and flow 
cytometry measurements showed that in H1152P-treated rECTs number of cells in 
G0/G1 phase decreased by 15%, whereas the number of cells in G2/M phase 
increased by 220% (Figure 29B). Using the same flow cytometry analysis, the 
number of NRCF that were double-nucleated was determined. In accordance with 
the results from the 2D culture of NRCF treated with H1152P, also in these cells a 




4.4.3 ROCK inhibition in ECT induces changes in genes associated with the 
cytoskeleton and the ECM 
Gene expression analysis by qPCR of rECT treated with Fasudil and H1152P 
showed that both kinases are involved in the expression of genes associated with 
cytoskeletal and ECM proteins, as well as the regulation and turnover of the ECM. 
For example, inhibition of ROCK using Fasudil and H1152P led to a 15.5-fold and 
2.6-fold increase in expression of elastin. Expression of its respective degrading 
enzyme elastase/matrix metalloproteinase 12 (MMP12) was significantly 
downregulated by 52% upon H1152P-treatment, whereas ROCK inhibition by Fasudil 
did not have an influence on MMP12 expression. Moreover, expression of 
hyaluronan synthase 2 (HAS2) was decreased by about 67% after treatment with 
both ROCK inhibitors. Expression of lysyl oxidase (LOX), an important mediator of 
the cross-linking of collagen and elastin, was reduced by 43% in Fasudil- and by 34% 
in H1152P-treated rECT [184]. Interestingly, the expression of collagens 1a1 and 
3a1, the collagen organisers biglycan and decorin, MMP2 and 9, and the pro-fibrotic 
factors CTGF and TGF was not affected by inhibition of ROCK activity in rECT. In 
addition, the expression of galectin-3 (LGALS3), which is upregulated in various 
types of tissue fibrosis and is considered to be a new biomarker for cardiovascular 





Figure 30: qPCR analysis of selected genes in control, Fasudil-, and H1152P-treated 
rECT. 
The change in mRNA in Fasudil- (10 µM) and H1152P-treated (3 µM) rECT relative to control 
rECT is given (means ±SEM, n=4-6, * p<0.05 vs. control, values were normalized to the 
mean of glucuronidase , PBGD, and vimentin). 
4.4.4 Inhibition of MMP12 does not alter viscoelastic properties of rECT 
As described above, elastin gene expression was found to be upregulated upon 
treatment of ECTs with the ROCK inhibitor H1152P, and expression of its respective 
elastase, MMP12, was downregulated. Therefore, it was tested whether inhibition of 
MMP12 alone shows a similar effect and whether inhibition of MMP12 and ROCKs at 
the same time has a cumulative effect. To investigate this, rECTs were generated 
from NRCF and collagen I and treated with H1152P (3 µM), MMP408 (3 µM), a 
specific MMP12 inhibitor, or both inhibitors. In Figure 31A, representative images of 
the rECT are depicted. The treatment of rECT with MMP408 did not increase the 
CSA of rECT, whereas H1152P-treated rECT showed an increase in CSA of about 
200% compared to control. However, combined treatment with MMP408 and H1152P 









Figure 31: Morphometric changes of rECT after MMP12 and ROCK inhibition. 
rECT were treated with H1152P (3 µM), MMP408 (3 µM) or both inhibitors. (A) Shown are 
representative images of the rECT. (B) Differences in calculated CSA of the different rECT 
are shown (means ±SEM, n=3, *p<0.05 vs. control, values illustrate numbers of rECT 
measured).  
To evaluate possible differences in viscoelastic properties, rECT were subjected to 
rheological destructive tensile strength measurement. In Figure 32, representative 
stress-strain curves of control, MMP408-, H1152P-treated rECT and those treated 
with both inhibitors are depicted. rECT treated with H1152P and with both inhibitors 
showed a flatter curve shape than control rECT, whereas those treated with MMP408 
alone slightly tolerated less stress than control. 
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Figure 32: Representative stress-strain curves of control, H1152P- and MMP408-
treated rECT during a rheological destructive tensile strength measurement. 
rECT were treated with H1152P (3 µM), MMP408 (3 µM) or both inhibitors. Shown are 
representative stress-strain curves for each condition.  
Stiffness as defined by the Young’s modulus was significantly reduced by 64% in 
H1152P- and by 61% in H1152P and MMP408-treated rECT. No change of stiffness 
was found in MMP408-treated tissues (Figure 33A). The maximum stress value was 
significantly decreased in H1152P-treated rECT (69%) and rECT treated with 
H1152P and MMP408 (66%, Figure 33B). Stress at the yield point was significantly 
decreased by 70% in H1152P-treated rECT and by 66% in rECT treated with both 
inhibitors (Figure 33C, left). No change was found regarding strain at the yield point 
(Figure 33C, right). Similarly, stress at the failure point was significantly decreased by 
70% in H1152P-treated rECT and by 67% in those treated with both inhibitors (Figure 
33D, left), whereas no change was observed for strain at the failure point (Figure 
33D, right). In summary, the inhibition of MMP408 alone was not sufficient to achieve 
the same decrease in stiffness as seen with ROCK inhibition by H1152P. Moreover, 





Figure 33: Analysis of the viscoelastic properties of control, H1152P- and MMP408-
treated rECT. 
Changes in (A) the Young’s modulus, (B) maximum stress value, (C) stress (left) and strain 
value (right) at the yield point, and (D) stress (left) and strain value (right) at the failure point 
are depicted (means ±SEM, n=3, * p<0.05 vs. control, values illustrate numbers of rECT 
measured). 
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4.4.5 Modelling tissue fibrosis using TGF1 as a stimulus 
Enhanced TGF1 signalling is known to increase the production of ECM and to 
induce fibrosis in various tissues. We therefore wanted to investigate whether 
inhibition of ROCK activity can have beneficial, “fibrosis-reducing” effects on 
viscoelastic properties of tissues that are treated with TGF1. To test this, rECTs 
were treated with H1152P (3 µM), TGF1 (5 ng/mL), or H1152P and TGF1 
together. Additionally, for some rECT, TGF1 treatment was stopped after three days 
and rECT treated with H1152P until rheological measurement was performed. As can 
be seen in Figure 34A, the treatment with TGF1 did not have a significant influence 
on the CSA of rECT compared to control. Treatment with H1152P increased the CSA 
of rECT, as described before.  
 
 
Figure 34: Morphometric changes of rECT after ROCK inhibition and TGFβ1 treatment. 
rECT were treated with H1152P (3 µM), TGFβ1 (5 ng/mL), or H1152P and TGFβ1. 
Additionally, for half of the TGFβ1-treated rECTs the treatment was stopped on day 3 and 
instead H1152P was added to the medium. (A) Shown are representative images of the 
rECT. (B) Differences in calculated CSA of the rECT are shown (means ±SEM, n=3, *p<0.05 











Interestingly, rECT treated with both TGF1 and H1152P slightly increased in size. 
This was even more striking in rECT for which TGF1-treatment was stopped after 
two days and continued with H1152P, as the CSA was significantly increased about 
3-fold compared to TGF1-treated rECT (Figure 34B). 
 
Next, viscoelastic properties of the rECT were assessed using rheological destructive 
tensile strength measurement. Representative stress-strain curves of control, 
H1152P, TGF1-, TGF1 and H1152P-treated, and rECT treated with TGF1 for two 
days and subsequently with H1152P for additional three days are depicted in Figure 
35. rECT treated with H1152P and both H1152P and TGF1 showed a flatter curve 




Figure 35: Representative stress-strain curves of control, H1152P- and TGFβ1-treated 
rECT during a rheological destructive tensile strength measurement. 
rECT were treated with H1152P (3 µM), TGFβ1 (5 ng/mL), TGFβ1 and H1152P, or TGFβ1 
until day 3, continued with H1152P until day 5. Shown are representative stress-strain curves 
for each condition.  
Analysis of the measurements showed that stiffness of TGF1-treated rECT did not 
change compared to control. However, additional treatment with H1152P significantly 
decreased the Young’s modulus by 60%. The effect of H1152P was even more 
striking when TGF1 treatment was stopped after two days (79% decrease; Figure 
36A). Maximum stress was decreased following treatment with H1152P alone (86%), 
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H1152P in combination with TGF1 (73%), and in TGF1-rECT in which H1152P 
treatment was started on day three (79%; Figure 36B). Stress at the yield and failure 
point was significantly decreased in rECT treated with H1152P (both 85%), TGF1 
and H1152P (both 75%), and in TGF1-rECT with H1152P added on day three (both 
79%; Figure 36C, D left). However, no difference was found regarding strain values 
at the yield and failure point (Figure 36C, D right). 
 
In summary, treatment with TGF1 was shown to have an effect on consolidation of 
rECT, rather than viscoelastic properties. TGF1 did not significantly change the 
stiffness of rECT compared to control and also did not have an effect when the rECT 
were additionally treated with H1152P. However, the increase in CSA observed in 





Figure 36: Analysis of the viscoelastic properties of control, H1152P- and TGF β1-
treated rECT. 
Changes in (A) the Young’s modulus, (B) maximum stress value, (C) stress (left) and strain 
value (right) at the yield point, and (D) stress (left) and strain value (right) at the failure point 
are depicted (means ±SEM, n=3, * p<0.05 vs. control, # p<0.05 vs. TGFβ1, values illustrate 
numbers of rECT measured). 
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4.5 ROCK1 and ROCK2 influence the contractility of engineered tissues and 
this is dependent on the maturation status of cardiomyocytes 
4.5.1 Inhibition of ROCK1 and ROCK2 has no influence on contractile 
parameters of rEHM 
In the next step, we wanted to investigate the effect of ROCK1 and ROCK2 on 
contractile and functional properties of engineered heart muscle (EHM). To do so, we 
constructed EHMs from primary neonatal rat cardiac cells (rEHM), collagen I and 
Matrigel. The rEHM were allowed to consolidate for seven days and then transferred 
onto phasic stretchers for mechanical load, which is essential for formation of a 
functional syncytium. During this phase, rEHM were treated with Fasudil (10 µM) and 
H1152P (3 µM). Previous results showed that treatment with H1152P resulted in an 
increase in force of contraction (FoC, Figure 7). However, FoC was not based on the 
CSA of the tissues, which was different between ROCK inhibitor-treated and control 
rEHM. Thus, experiments were repeated to evaluate the effect of ROCK inhibition on 
contractility of rEHM. Figure 37 shows, that rEHM treated with Fasudil and H1152P 





Figure 37: Morphometric changes of engineered heart muscle from neonatal cardiac 
cells of the rat (rEHM) after ROCK inhibition. 
rEHM were cultured for 7 days until they were fully consolidated and then transferred onto 
phasic stretchers for mechanical load for another 7 days. During this phase, rEHM were 
treated with Fasudil (10 µM) and H1152P (3 µM). (A) Shown are representative images of 
control-, Fasudil-, and H1152P-treated hEHM. (B) Differences in calculated CSA of the rEHM 
are shown (means ±SEM, n=5, *p<0.05 vs. control, values illustrate numbers of rEHM 
measured). 
On culture day 14, rEHM were subjected to isometric force measurement under 
increasing extracellular calcium. Fasudil and H1152P-treated rEHM showed a 
reduced resting force per CSA compared to control, which was independent of the 
calcium concentration (Figure 38A). In contrast to previous results, FoC per CSA in 
ROCK inhibitor-treated rEHM was not different to control rEHM, although a slight 
trend towards an increased contractility could be detected (Figure 38B). Similarly, no 
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Figure 38: Isometric force measurement of control-, Fasudil-, and H1152P-treated 
rEHM. 
(A) Analysis of resting force normalized to the CSA at different calcium concentrations, (B) 
Analysis of the force of contraction (FoC) normalized to the CSA at different calcium 
concentrations, (C) Bar graph summary of the calculated EC50 for Ca2+ (means ±SEM, n=8, 
29-31 rEHM measured in total, * p<0.05 vs. control). 
4.5.2 Inhibition of ROCK1 and ROCK2 activity influences viscoelastic 
properties of rEHM 
After performing isometric force measurements, rEHM were subjected to rheological 
destructive tensile strength measurement to evaluate viscoelastic properties of the 
tissues. Representative stress-strain curves can be seen in Figure 39.  
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Figure 39: Representative stress-strain curves of control, Fasudil-, and H1152P-treated 
rEHM during a rheological destructive tensile strength measurement. 
rEHM were treated with Fasudil (10 µM) or H1152P (3 µM). Shown are representative stress-
strain curves for each condition.  
Similar to rECT, the Young’s modulus of Fasudil- and H1152P-treated rEHM was 
reduced 31% and 45%, respectively (Figure 40A). In addition, maximum stress was 
decreased by about 45% in both conditions compared to control (Figure 40B). Less 
ultimate stress was needed until the yield point and failure point were reached, as 
stress was decreased by 44% in Fasudil- and by 48% in H1152P-treated rEHM for 
both yield and failure point (Figure 40C, D left). ROCK inhibitor treatment did not 




Figure 40: Analysis of the viscoelastic properties of control, Fasudil-, and H1152P-
treated rEHM. 
Changes in (A) the Young’s modulus, (B) maximum stress value, (C) stress (left) and strain 
value (right) at the yield point, and (D) stress (left) and strain value (right) at the failure point 
are depicted (means ±SEM, n=3, * p<0.05 vs. control, values illustrate numbers of rEHM 
measured). 
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4.5.3 Inhibition of ROCK activity decreases contractile force of hEHM 
To evaluate the influence of ROCK signalling on contractility of EHM in the human 
model, hEHMs were constructed from a mixture of hES2 wt CM, NHCF-V and 
collagen I. As only two cell types were added, namely cardiomyocytes and cardiac 
fibroblasts, this model is considered more defined than the rEHM model. The hEHM 
were allowed to consolidate for three days and then transferred to dynamic 
stretchers. hEHM were treated either from day zero or day three with H1152P (3 µM). 
No change in CSA was detected after H1152P-treatment (Figure 41). 
 
 
Figure 41: Morphometric changes of engineered heart muscle from hES2 wt CM and 
NHCF-V (hEHM). 
hEHM were cultured for 3 days until they were fully consolidated and then transferred onto 
dynamic mechanical stretchers for mechanical loading for another 25 days. hEHM were 
treated with H1152P (3 µM) from day 0 or day 3 on. (A) Shown are representative images of 
control hEHM and those treated with H1152P day 0 and day 3. (B) Bar graph summary of 
the calculated CSA of the hEHM are shown (means ±SEM, n=4-7, >25 hEHMs measured 
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On culture day 28, hEHM were subjected to isometric force measurement under 
increasing extracellular calcium. The relative resting force per CSA of day 0 and 
day 3 H1152P-treated hEHM showed no difference compared to control (Figure 
42A). However, FoC per CSA of hEHM that were treated with H1152P on day 0 and 
day 3 was significantly reduced compared to control. The effect of H1152P was most 
striking in hEHM that were treated from day 0 (Figure 42B). Interestingly, no change 
in EC50 Ca2+ was found (Figure 42C). 
 
 
Figure 42: Isometric force measurement of control- and H1152P-treated hEHM. 
(A) Analysis of the relative resting force normalized to the CSA at 2 mM extracellular Ca2+ 
with resting force/CSA of control set to 100%, and (B) Analysis of FoC normalized to the 
CSA at different calcium concentrations (means ±SEM, n=8, 29-31 rEHM measured in total, * 
p<0.05 vs. control). (C) Bar graph summary of the calculated EC50 for Ca2+ (means ±SEM, 
n=4-7, >18 hEHMs measured per condition). 
In Figure 43A and B, representative force traces and curves of a single contraction of 
the different groups are depicted. Analysis of single contractions revealed that 
treatment of hEHM with H1152P significantly decreased the amplitude of contraction 









addition, contraction time was slowed in hEHM that were treated with H1152P from 
day 0, as 90% time-to-peak was decreased by 9% and 50% time-to-baseline by 11%. 
Contraction time in H1152P Day 3 hEHM was similar to control. 
 
 
Figure 43: Analysis of force traces of control- and H1152P-treated hEHM. 
(A) Representative force traces recorded by isometric force measurements in day 28 control- 
and H1152P-treated hEHMs. (B) Representative curves of a single contraction of control- 
and H1152P-treated hEHMs. Bar graph summary of (C) amplitude, (D) 90% time-to-peak, 
and (E) 50% time-to-baseline (means ±SEM, n=4-7, >18 hEHMs measured per condition, 
* p<0.05 vs. control). 
4.5.4 Inhibition of ROCK1 and ROCK2 activity does not change viscoelastic 
properties of hEHM 
Next, hEHM were subjected to rheological destructive tensile strength measurement 
to evaluate viscoelastic properties of the tissues. Representative stress-strain curves 











Figure 44: Representative stress-strain curves of control and H1152P-treated hEHM 
during a rheological destructive tensile strength measurement. 
hEHM were treated with H1152P (3 µM) from day 0 or day 3 on. Shown are representative 
stress-strain curves for each condition.  
In accordance with the results of the resting force, analysis of the Young’s modulus, 
maximum stress, yield, and failure point showed no differences between H1152P-





Figure 45: Analysis of the viscoelastic properties of control and H1152P-treated hEHM. 
Changes in (A) the Young’s modulus, (B) maximum stress value, (C) stress (left) and strain 
value (right) at the yield point, and (D) stress (left) and strain value (right) at the failure point 









4.6 Outlook: Finding new selective targets for ROCK1 and ROCK2 
4.6.1 Identification of new potential ROCK targets 
The role of ROCK1 and ROCK2 has long been considered to be similar, especially 
because they mostly share common targets and functions. The only well-
characterized specific substrate is Rnd3 (also known as RhoE), which was shown to 
be phosphorylated by ROCK1 but not ROCK2 [77]. Thus, the aim was to find new 
potential selective targets for ROCK1 and ROCK2 using PamGene’s kinase activity 
profiling technology. The system is based on detecting peptide phosphorylation by 
kinases on a microarray using a mixture of primary and fluorescently labelled 
secondary antibodies.  
 
A representative image of a microarray after a successful experiment can be seen in 
Figure 46A. First, different protein amounts of ROCK1 and ROCK2 were applied to 
the microarray. Of all peptides that were phosphorylated by ROCK1 and ROCK1, the 
peptides corresponding to a sequence in the human p21 protein (Figure 46B) and the 
human cyclin-dependent kinase 7 (CDK7) protein (Figure 46C) were chosen for 
further analysis. p21, also known as cyclin-dependent kinase inhibitor 1 or CDK-
interacting protein 1, is a potent inhibitor of cyclin-CDK1, -CDK2, and –CDK4/6 
complexes and proliferating cell nuclear antigen (PCNA). It has been shown that p21 
regulates cell cycle progression at G1 and S phase, thus mediating growth arrest, 
differentiation or senescence [186]. CDK7 acts as a CDK activating kinases and can 
additionally be part of the transcription factor TFIIH, which is involved in transcription 
initiation by phosphorylating the C-terminal domain of RNA polymerase II. Both p21 
and CDK7 were chosen, as knockdown and inhibition of ROCKs had an impact on 
the cell cycle and proliferation of cardiac fibroblasts.  
 
In Figure 46B and C, quantification of the fluorescence intensity for the 
phosphorylation of the peptides corresponding to human p21 and CDK7 protein 
dependent on the protein amount of ROCK1 and ROCK2 is shown. As expected, 
fluorescence intensity was increased the more amount of kinase protein was used, 
proving the quantitative nature of the assay. Interestingly, p21 seemed to be a much 
better target for ROCK1 and ROCK2, than CDK7. In a different approach, ROCK1 
and ROCK2 were treated with H1152P (3 µM) or the putative ROCK2-selective 
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inhibitor SLx-2119 (3 µM) prior to performing the assay (Figure 46D, E). As can be 
seen in Figure 46D and E, pre-treatment with H1152P mostly resulted in a slight 
decrease of phosphorylation activity. Only phosphorylation of CDK7 by ROCK2 was 
diminished by H1152P treatment. Interestingly, pre-treatment with SLx-2119 did not 
lead to changes in p21 phosphorylation, but slightly decreased CDK7 
phosphorylation by ROCK2. 
 
 
Figure 46: Identification of new ROCK targets using PamGene’s kinase activity 
profiling technology. 
(A) Representative fluorescent image showing one PamChip microarray after 
termination of the assay. The microarray consists of 140 Ser/Thr containing peptides 
and 4 positive control phosphorylated peptides. (B, C) Quantification of the 
fluorescence intensity for the phosphorylation of the peptide corresponding to a 
sequence in (B) the human p21 protein and (C) the human CDK7 protein. Different 
amounts of purified kinase were used (ROCK1: 0.1-20 ng; ROCK2: 0.02-20 ng; n=1). 
(D, E) The purified kinases were treated with ROCK inhibitor H1152P (3 µM) or 
ROCK2-specific SLx-2119 (3 µM) prior to performing the assay. Bar graph summary 
of the fluorescence intensity for phosphorylation of peptides corresponding to specific 
sequences in human p21 und CDK7 proteins by (D) ROCK1 and (E) ROCK2. 10 ng 








4.6.2 p21 and CDK7 are phosphorylated by ROCK1 and ROCK2 in vitro 
In 4.6.1 it was shown that ROCK1 and ROCK2 can phosphorylate peptides of 13 
amino acids corresponding to a sequence in the human p21 and CDK7 proteins. In 
order to investigate if p21 is phosphorylated by ROCK1 and ROCK2, purified 
recombinant p21 protein was incubated with purified ROCK1 and ROCK2 in an in 
vitro kinase assay. Additionally, ROCK1 and ROCK2 were incubated with Histone H1 
protein as a positive control and GST protein to rule out that ROCK1 and ROCK2 
phosphorylate the GST-tag of the recombinant p21. Using [γ-32P]ATP, p21 was 
shown to be phosphorylated by both ROCK1 and ROCK2 (Figure 47A). In the next 
step, purified ROCK1 and ROCK2 were incubated with H1152P (3 µM) or SLx-2119 
(3 µM) prior to performing the in vitro kinase assay. As can be seen in Figure 47B, 
treatment with ROCK inhibitors did not decrease phosphorylation of p21, but 







Figure 47: p21 is phosphorylated by ROCK2 and ROCK2 in an in vitro kinase assay. 
(A) Purified recombinant p21 protein, histone H1, or GST (2 μg each) were incubated with 
purified ROCK1 or ROCK2 in an in vitro kinase assay in the presence of [γ-32P]ATP. Proteins 
were resolved by SDS–PAGE and protein phosphorylation was detected by autoradiography. 
(A) Representative autoradiography of in vitro kinase assay showing the phosphorylation of 
p21 by ROCK1 and ROCK2 (n=3). (B) Purified ROCK1 and ROCK2 were incubated with 
H1152P (3 µM) or SLx-2119 (3 µM) prior to performing the in vitro kinase assay. Shown is a 
























































































































































































To prove that also CDK7 is phosphorylated by ROCK1 and ROCK2, purified inactive 
CDK7 protein was incubated with purified ROCK1 and ROCK2 in the presence of [γ-
32P]ATP. Also in this experiment, ROCK1 and ROCK2 were pre-treated with H1152P 
(3 µM) or SLx-2119 (3 µM) prior to performing the in vitro kinase assay. Interestingly, 
a weak phosphorylation of CDK7 could already be detected without the addition of 
ROCK1 or ROCK2, arguing for an autophosphorylation of CDK7, although the 
purified protein ought to be inactive. However, phosphorylation of CDK7 by ROCK1 




Figure 48: CDK7 is phosphorylated by ROCK2 and ROCK2 in an in vitro kinase assay. 
Purified recombinant CDK7 protein (2 μg) were incubated with purified ROCK1 or ROCK2 in 
an in vitro kinase assay in the presence of [γ-32P]ATP. Additionally, ROCK1 and ROCK2 
were incubated with H1152P (3 µM) or SLx-2119 (3 µM) prior to performing the in vitro 
kinase assay. Proteins were resolved by SDS–PAGE and protein phosphorylation was 
detected by autoradiography. Shown is a representative autoradiography of in vitro kinase 














































































































4.6.3 p21 and ROCK1 interact in cells 
To investigate whether p21 and ROCK1 can associate with each other in cells, 
HEK293A cells were co-transfected with plasmids encoding FLAG-p21 together with 
myc-ROCK1 wt or myc-ROCK11, a constitutively active C-terminally truncated 
ROCK 1 (Figure 49A). As can be seen in Figure 49B, p21 co-immunoprecipitated 




Figure 49: p21 co-immunoprecipitates with ROCK1. 
(A) Lysates of HEK293A cells expressing FLAG-p21 and myc-ROCK1 wt or myc-ROCK11 
were separated by SDS-PAGE followed by immunoblotting. Overexpression of myc-ROCK1 
wt, myc-ROCK11, and FLAG-p21 was confirmed using anti-myc and anti-p21 antibodies, 
respectively. (B) Lysates were subjected to immunoprecipitation with anti-myc beads. The 





During the progression of disease, the heart undergoes structural, as well as 
functional changes. Most work so far focused on the behaviour of cardiomyocytes in 
pathological conditions. However, it is becoming appreciated that cardiac fibroblasts 
represent not only the predominant non-myocyte cell population in the heart and are 
essential for maintaining homeostasis and functionality of the myocardium, but after 
transdifferentiation into myofibroblasts also play a critical role in the pathogenesis of 
cardiac hypertrophy, remodelling and heart failure [187]. It is known so far that cFBs 
communicate with CMs by secretion of paracrine acting factors via direct cell-cell 
contacts and through secretion and remodelling of the ECM. However, the 
mechanisms behind what drives the activation and transdifferentiation of cFBs into 
myofibroblasts remain largely unknown [188]. In this regard, Rho-associated kinases 
ROCK1 and ROCK2 are known to play a critical role in the pathogenesis of 
myocardial fibrosis; however, their specific function in cFBs remains unclear [3]. In 
previous experiments, a knockdown of ROCK1 and of both kinases was established 
in NRCF using lentiviral delivery of shRNAs. Here it was shown that ROCK signalling 
has an influence on cFB morphology and that knockdown of ROCK1 and ROCK2 
together stops proliferation of cFBs. Moreover, in engineered connective tissue 
(ECT) and engineered heart muscle (EHM) an effect of ROCK inhibition on 
viscoelastic and contractile properties, respectively, could be observed. Thus, the 
hypothesis was that ROCK1 and ROCK2 have an impact on cFB characteristics and 
are important mediators of myofibroblast differentiation. In this study, it was 
demonstrated that: 
 
I. ROCK1 and ROCK2 control myofibroblast characteristics like remodelling of 
the actin cytoskeleton, adhesion, migration, and proliferation in cardiac 
fibroblasts. 
II. ROCK signalling affects ECM protein expression and ECM remodelling. 
III. ROCKs are important mediators of viscoelastic and contractile properties of 




5.1 ROCK1 and ROCK2 influence morphology and the actin cytoskeleton of 
cardiac fibroblasts 
To investigate the influence of ROCK1 and ROCK2 signalling further, first an isoform 
selective knockdown of ROCK1 and ROCK2 was established in NRCF via 
transfection of siRNAs (Figure 14). Moreover, NRCF were treated with the non-
selective ROCK inhibitors Fasudil and H1152P to investigate the effect of an 
inhibition of ROCK activity.  
 
As ROCK1 and ROCK2 are known to be major regulators of the cytoskeleton in 
various cell types, the effect of ROCKs on NRCF morphology was evaluated. Upon 
knockdown of ROCK1 or ROCK2, as well as after treatment with ROCK inhibitors, an 
increase in NRCF area was observed (Figure 15). Moreover, the actin cytoskeleton 
was found to be disturbed, as the formation of geodesic actin domes was reduced. 
Interestingly, geodesic domes were most abundant in lentiviral transduced NRCF 
compared to those transfected with siRNAs or treated with inhibitors, suggesting that 
their formation might also be a reaction to the increased stress provided by the 
lentivirus (Figure 16). Geodesic domes are very rare and highly organised actin 
structures consisting of specifically ordered polygonal elements. The function of 
these structures is not clear so far, however, geodesic domes are postulated to be 
highly stable structures which can provide resistance against tension or compression 
[189]. Moreover, it has been shown that geodesic domes and stress fibres can 
transform into each other in neonatal rat cardiac fibroblasts [190]. In line with the 
findings of this study, Malek et al. showed that using the Rho inhibitor C3 transferase 
and the ROCK inhibitor Y-27632 the formation of these actin structures was 
suppressed in hypertonic endothelial cells and is thus dependent on RhoA/Rock 
signalling [191]. Loss of stress fibres and geodesic domes leading to reduced 
intracellular tension could also partly explain the increase in cell area observed 
following ROCK knockdown and inhibition of ROCK activity [189]. Furthermore, 
ROCK inhibition by H1152P has already been shown to lead to an increase in cell 
area accompanied by a reduction in stress fibre formation in lung fibroblasts [192]. 
Also, one of the major effects of ROCK signalling is an increased actomyosin 
contractility by phosphorylation of MYPT1 and MLC [45, 104]. Decreased actomyosin 
contractility due to a knockdown or inhibition of ROCK1 and ROCK2 could increase 
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the main area per cell. Additionally, knockdown of RhoA, one of the major activators 
of ROCKs, also led to an increase in cell size in NRCF [126]. 
 
Although a strong effect on NRCF morphology after downregulation of ROCKs could 
be seen, no change in the expression of the focal adhesion protein vinculin or 
cytoskeletal proteins, as for example β-actin, α-tubulin or the myofibroblast marker 
αSMA could be detected by immunoblot analyses (Figure 17). The expression of 
αSMA and the activity of its regulator serum response factor (SRF) were previously 
shown to be decreased in NRCF with a downregulation of RhoA [126]. Moreover, 
inhibition of RhoA with C3 transferase inhibited the angiotensin II-induced activation 
of SRF in NRCF. In contrast, treatment with H1152P to inhibit ROCKs was not 
sufficient to inhibit the angiotensin II-induced activation of SRF in NRCF, which might 
in part explain why no change in α-sm-actin expression could be found [193]. 
Although the RhoA/ROCK pathway was previously shown to activate SRF, the 
activation itself is Rho dependent and ROCK activity does not always appear 
necessary for this process. Thus, other RhoA effectors like mDia, citron kinase, or 
PLC might be of greater importance in this process than ROCKs [194]. 
 
 
5.2 ROCK1 and ROCK2 are essential players in cardiac fibroblast adhesion and 
migration 
Although vinculin protein expression was found unchanged, ROCK1 and ROCK2 
knockdown NRCF adhered faster than their respective control cells. No difference 
between adhesion velocity of the ROCK1 or ROCK2 knockdown was observed 
(Figure 18). An explanation for the changed adhesion behaviour might be that 
ROCK1 and ROCK2 knockdown NRCF had more focal adhesions (FAs) than control 
NRCF. The size of single FAs and the overall area of all FAs per cell were increased 
in ROCK1 knockdown NRCF. In contrast, ROCK2 knockdown NRCF had smaller 
FAs and the overall area per cell was unchanged (Figure 19). Focal adhesions are 
complexes that link actin stress fibres to the ECM. The important role of ROCKs in 
adhesion processes has mostly been investigated in cancer research together with 
migration [195]. For example, three activating genetic ROCK1 mutations have been 
shown to decrease adhesion in lung carcinoma cells [196]. It has been postulated 
that Rho/ROCK signalling regulates cell adhesion by enhancing actomyosin 
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contractility, however the exact mechanism is not clear so far. One possible 
mechanism involves Na+/H+ exchanger 1 (NHE1), which can be phosphorylated by 
ROCKs and is known to mediate the turnover and assembly of FAs, thereby possibly 
contributing to cell migration [197, 198]. Moreover, recent data from our group 
showed that also after RhoA knockdown in NRCF, adhesion velocity was increased. 
Interestingly, RhoA knockdown NRCF had smaller FAs, similar to the ROCK2 
knockdown [126].  
 
The changes in cFB morphology and adhesion also had an impact on migratory 
behaviour of the ROCK1 and ROCK2 knockdown NRCF. In this study, the 
knockdown of ROCK1 and ROCK2 decreased migration velocity and absolute 
migrated distance on a focal plane (Figure 20). The involvement of ROCK1 and 
ROCK2 in cardiac fibroblast migration has not been investigated in great detail so far. 
However, several studies are available focussing on ROCKs and migration in cancer 
cells, which confirmed our findings for the planar migration [195, 199, 200]. In 
general, it is known that for all migratory processes, a dynamic remodelling of the 
actin cytoskeleton is essential. This is usually regulated by the RhoGTP family: 
Cdc42 has been shown to be important for cell polarity and together with Rac 
controls the formation and turnover of lamellipodia and focal complexes, whereas 
Rho/ROCK signalling is important for actomyosin contraction at the rear of the cell to 
facilitate tail retraction. However, as Rho activity also plays a role in the formation of 
focal adhesions, a strong activity rather inhibits migration [201, 202]. There are 
different types of fibroblast migration: the lamellipodia-dependent, mesenchymal 
migration which requires cell polarity, the blebbing-dependent amoeboid migration, 
and an intermixed way, termed lobopodia-dependent migration. Fibroblasts have 
been shown to mostly migrate lamellipodia-dependent in culture, and lamellipodia- or 
lobopodia-dependent in a 3D environment, depending on the matrix and also on the 
activity of RhoA [203, 204]. In this study, not only the migration on a focal plane, but 
also the invasive migration of NRCF with a knockdown of both kinases in a transwell 
migration assay was found to be reduced (Figure 23). This is especially interesting as 
the invasive migration of myofibroblasts in remodelling processes is essential for the 




In contrast, knockdown of both kinases, as well as inhibition of ROCK activity using 
H1152P, had an opposing effect on the migratory behaviour of NRCF, as velocity 
and absolute migrated distance of NRCF were both significantly increased (Figure 
21). These findings were quite unexpected. However, it has already been shown in 
cancer cells that inhibition of ROCK sometimes leads to contradicting effects on cell 
migration. For example, ROCK inhibition by Y-27632 in MCF-7 breast cancer cells 
led to enhanced migration and invasion of these cells, partly due to a loss of E-
cadherin and -catenin from the cell membrane and activation of Rac1 signalling 
[205]. The contradicting effects of ROCK inhibition on cancer cells is usually 
attributed to the high plasticity of these cells, as well as an upregulation of other 
pathways like Rac signalling [195]. Due to the fact that both ROCKs are affected in 
the double knockdown or after inhibition with H1152P, an upregulation of other 
GTPase pathways involved in migration like Rac1 or Cdc42 is likely. For example, 
activation of Cdc42 and subsequent activation of the kinase Pak2 can also promote 
actomyosin contractility similar to RhoA/ROCK signalling by phosphorylation of MLC 
at Ser19, thereby activating myosin-II [206].  
 
 
5.3 ROCK1 and ROCK2 control proliferation of cardiac fibroblasts 
Myofibroblasts are also characterised by an increased proliferative capacity when 
compared to quiescent cardiac fibroblasts. Analysis of proliferation in response to a 
serum stimulus showed that only if both ROCK1 and ROCK2 were affected, i.e. after 
inhibition of ROCK activity by H1152P, proliferation of NRCF was diminished (Figure 
24). This has already been shown for the double knockdown in NRCF (Figure 6) and 
it is in line with findings from other groups. For example, simvastatin, a HMG-CoA 
reductase inhibitor that inhibits RhoA geranylgeranylation thereby preventing its 
association to the plasma membrane, inhibited the FCS-driven proliferation of human 
atrial myofibroblasts. This effect could be mimicked by treatment of the cells with the 
ROCK inhibitor Y-27632, proving an involvement of ROCK signalling [128]. Similarly, 
the ROCK inhibitor GSK-576371 was shown to reduce angiotensin II and TGF1-
induced proliferation of NRCF [207]. In contrast to these findings, downregulation of 
either ROCK1 or ROCK2 did not have an effect on cFB proliferation, suggesting that 
at least in cFB, this process is dependent on both ROCK1 and ROCK2, or that they 




The reason for the effect on cFB proliferation was further investigated and it was 
found that H1152P treatment might lead to a cytokinesis defect in NRCF. H1152P-
treated NRCF failed to divide, which resulted in a higher percentage of double-
nucleated cells. Another finding that supports the hypothesis of a cytokinesis defect 
is that H1152P-treated NRCF within engineered tissues were found to be 
increasingly present in G2M phase when compared to control tissues (Figure 25). 
Cytokinesis is a complex process that occurs in four stages: (I) Specification of the 
cleavage plane and recruitment of RhoA, a central regulator of cytokinesis, to the 
cleavage site; (II) Furrow ingression by formation of an actomyosin ring; (III) Midbody 
formation and stabilisation of the cytokinetic furrow by compacting the central spindle 
microtubules; (IV) Abscission of the furrow by separation of the cytoplasm of the 
daughter cells [208]. ROCKs play a vital role during the second phase, the ingression 
of the cleavage furrow. They have been shown to localise at the cleavage furrow and 
contribute together with citron kinase to myosin activation by phosphorylating MLC at 
Thr18 and Ser19, which is important for proper localization of myosin to the furrow 
[209-213]. However, it can be assumed that ROCKs and citron kinase have partially 
overlapping functions, as treatment with Y-27632 and Fasudil significantly slowed the 
cleavage, but did not stop it [212]. 
 
Using kinase activity profiling, in vitro kinase assays and immunoprecipitation, p21 
and CDK7 were identified as potential new ROCK substrates (Figure 46-Figure 49). 
p21 is a multifunctional protein that is usually upregulated in response to cellular 
stresses as for example DNA damage or oxidative stress, to arrest the cell cycle. It 
primarily does so by acting as a CDK inhibitor by binding to CDK2 and CDK1 and 
inhibiting their activity. Depending on the binding partner, this leads to growth arrest 
at specific stages of the cell cycle. Moreover, p21 also binds proliferating cell nuclear 
antigen (PCNA), thereby interfering with its DNA-polymerase activity and inhibiting 
DNA replication, as well as modulating PCNA-dependent DNA repair processes 
[186]. Each peptide on the PamGene chip represents a 15 amino acid sequence, of 
which 13 residues were derived from the phosphorylation site in the respecting 
human protein, in this case amino acids 139-151 of p21. Phosphorylation of p21 at 
the potential ROCK phosphorylation site Thr145 by Akt1/PKB and PKA was shown to 
inhibit binding to PCNA [214, 215]. Phosphorylation of Ser146 by Akt1/PKB 
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increased p21 stability and promoted cell survival, whereas PKC inhibited PCNA 
binding [215, 216]. The putative phosphorylation of p21 by ROCK1 or ROCK2 could 
have a negative regulatory effect on p21 function, as knockdown or inhibition of 
ROCKs stops proliferation of cFBs. 
 
CDK7 on the other hand has a dual function in cell cycle control and transcription. It 
can act as a CDK-activating kinase by phosphorylating cell cycle CDKs within their 
activating T-loop, which together with binding to the respective cyclin is required for 
full activity of the kinases. Moreover, CDK7 is part of the transcription factor TFIIH, 
which is known to phosphorylate the C-terminal domain of DNA polymerase II [217]. 
In the case of CDK7, the 13 residues on the PamGene chip were derived from the 
phosphorylation site involving amino acids 163-175 of CDK7. Both potential ROCK 
phosphorylation sites, Ser164 and Thr170 have been linked to the regulation of 
transcriptional activity by CDK7 [218-220]. By this, also ROCK could interfere with 
transcription and cell cycle progression. 
 
 
5.4 ROCK signalling influences the regulation and turnover of the ECM and 
thus viscoelastic properties of engineered tissues 
In order to study the functional role of cardiac fibroblasts regarding regulation of the 
ECM in a more physiological model, ECT consisting of cardiac fibroblasts and 
collagen I as a hydrogel were utilised. ROCK inhibitor-treated tissues were less 
consolidated than control tissues with an increase in CSA (Figure 26). Using 
destructive tensile strength measurement, it was demonstrated in this study that not 
only in the rat, but also in the human model, treatment of ECT with ROCK inhibitors 
altered their viscoelastic properties. Stiffness as defined by the Young’s modulus was 
decreased in ROCK inhibitor-treated tissues. Also, these tissues tolerated less 
maximal stress and more ultimate stress was needed until the yield and failure point 
were reached (Figure 33).  
After it was excluded that the observed changes were due to a different amount of 
cells in the tissues, i.e. due to an altered proliferation, gene expression analysis of 
ECM genes was performed. Inhibition of ROCK activity in ECT increased elastin 
gene expression and decreased the expression of its respective degrading enzyme 
MMP12 (Figure 30). Elastin is a major component of the extracellular matrix and its 
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major biological function is to give elasticity to organs and tissues, thereby allowing 
them to resume their shape after stretching or contracting [221]. Genomic mutations 
in the elastin gene have been shown to play a role in supravalvular aortic stenosis, 
which causes narrowing of the large arteries [222]. Translocations or point mutations 
in the gene lead to a truncated form of elastin which lacks important crosslinking 
domains, resulting in the deposition of abnormal elastin fibres [222, 223]. With the 
help of the ECT model, it was tested whether an increase in the amount of elastin 
fibres by inhibiting its degrading enzyme MMP12 using a small molecule inhibitor, 
MMP408, had a similar effect on the viscoelastic properties of the ECT as ROCK 
inhibition. However, treatment with MMP408 alone did not alter cross-sectional area 
or viscoelastic properties of the ECT when compared to control tissues, and 
simultaneous treatment with H1152P did not lead to a cumulative effect (Figure 31, 
Figure 32). These results suggest that increased expression of elastin and decreased 
expression of MMP12 is not the only mechanism underlying the observed effects in 
ROCK inhibitor-treated tissues. 
 
Also, the expression of the collagen and elastin crosslinking enzyme lysyl oxidase 
was found to be decreased upon ROCK inhibition (Figure 30). Lysyl oxidase is of 
considerable importance in heart disease, as the degree of collagen crosslinking 
determines its thickness, stiffness, and resistance to degradation and thus affects 
myocardial dysfunction [184]. In heart failure patients, lysyl oxidase expression was 
found to be increased, and the resulting enhanced collagen crosslinking had an 
impact on increased LV stiffness and filling pressures [224, 225]. Thus, reduced 
expression of lysyl oxidase in ROCK inhibitor-treated ECT might lead to less 
crosslinking of collagens and elastin, resulting in the observed decrease in tissue 
stiffness. 
 
Interestingly, expression of typical collagens and MMPs, as for example collagens 
1a1 and 3a1, and MMP2 and 9, as well as of the collagen organisers biglycan and 
decorin, and the pro-fibrotic factors CTGF and TGF was not affected (Figure 30). 
These results are in contrast to findings from other groups in cultured cells. For 
example, Akhmetshina et al. demonstrated in scleroderma fibroblasts that expression 
and synthesis of the ECM proteins fibronectin, collagen 1a1, and collagen 1a2 was 
decreased upon ROCK inhibition. However, in accordance to this study, no change in 
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expression of MMPs was detected [226]. In contrast, several independent groups 
have shown that ROCK inhibitor treatment can lead to diminished expression of 
MMP2 and MMP9 in various cell types [227-229]. Until now, these discrepancies 
cannot be explained satisfactorily.  
 
Due to its 3D properties, the ECT model provides a more physiological environment 
for the cardiac fibroblasts than a 2D culture and might thus prevent their immediate 
transition into myofibroblasts, which usually happens during culturing. Effects of 
ROCK inhibition on ECM protein expression and secretion might therefore not be as 
obvious. For this reason, a different approach was to push the transdifferentiation of 
cFBs to myofibroblasts by treatment of ECT with TGF1. It was found that treatment 
with TGF1 together with H1152P had an effect on consolidation of ECT, but not on 
their viscoelastic properties (Figure 34, Figure 36). It is known that canonical (SMAD) 
and non-canonical (MAPK-p38) TGF signalling is sufficient to initiate cardiac 
fibroblast to myofibroblast transdifferentiation by inducing the transcription of ECM 
and smooth muscle contractile genes. In contrast, the Rho/ROCK-MRTF-SRF 
pathway gets activated later in the process and then helps cement the phenotype 
[230]. Thus, simultaneous treatment of ECT with TGF and H1152P might be 
sufficient to alter consolidation properties, i.e. decrease the CSA of rECT as there is 
already a change in ECM composition. However, this is insufficient to alter 
viscoelastic characteristics as the Rho/ROCK-MRTF-SRF pathway is blocked. This 
might in part explain why rECT that were treated with TGF1 and H1152P showed a 
decreased CSA compared to H1152P treatment alone, whereas stiffness was similar 
to H1152P-treated rECT. In addition, as treatment with TGF1 alone did not increase 
tissue stiffness compared to control, a higher concentration of TGF1 might be 
needed to adequately push cFB to myofibroblast transition in the ECT model. 
 
 
5.5 ROCK1 and ROCK2 have an influence on the contractility of EHM 
As ROCK inhibition led to a reduced stiffness in ECT, it was investigated whether this 
applies also for heterogeneous tissues consisting of cFBs and CMs and if so, 
whether a decreased stiffness influences contractile properties of EHM.  
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First, engineered tissues consisting of cFBs and CMs to model heart muscle were 
subjected to rheological destructive tensile strength measurement to evaluate 
viscoelastic properties of these tissues. Similar to rECT, the Young’s modulus and 
maximum stress of Fasudil- and H1152P-treated rEHM was reduced and less 
ultimate stress was needed until the yield point and failure point were reached 
(Figure 40). This suggests that the influence of cFBs on the regulation and turnover 
of the ECM applies also for the heterogeneous heart muscle model. However, 
analysis of hEHM consisting of NHCF-V and hES2 wt CM treated with H1152P did 
not show any differences in viscoelastic properties, although a trend towards a 
reduced stiffness could be detected (Figure 45). When comparing the stress-strain 
curves of EHM versus ECT in destructive tensile strength measurements it became 
apparent that there are certain differences. For example, EHM usually had a clear 
defined failure point as these tissues ruptured instantaneously when reaching the 
point. In contrast, ECT ruptured much slower, usually starting at one point and then 
slowly continuing over several seconds. In addition, ECT were stiffer, as the Young’s 
modulus was significantly higher. This showed that due to the distinct cell 
composition of the tissues, EHM rather behave as an elastic material, whereas ECT 
behave as a viscous material in destructive tensile strength measurements.  
 
To analyse functional parameters of the EHM, the tissues were subjected to 
isometric force measurement under increasing extracellular calcium. In the rat model, 
Fasudil- and H1152P-treated rEHM showed a decreased resting force (Figure 38). 
This is in accordance to the findings from the rheological measurements, as the 
resting force is also a measure for stiffness of the EHM. In the human model, no 
change in resting force could be detected, which supports the rheological data 
(Figure 42).  
 
Interestingly, in the rat model, no effect of ROCK inhibition on force of contraction 
was found. In addition, there was no effect on EC50 Ca2+ (Figure 38). In the human 
model, force of contraction was significantly reduced after H1152P treatment from 
day three of culturing, and even further if ROCKs were inhibited directly from the 
beginning. Also in hEHM there was no change in EC50 Ca2+ (Figure 42). So far, these 
findings cannot be explained to full extent. For the human EHM model, CMs derived 
from human embryonic stem cells (hES2 wt CM) were utilised, which resemble the 
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maturation status of embryonic CMs, and for rEHM neonatal CMs were used. It was 
already demonstrated in the rat that the EHM model induces further maturation of 
initially immature CMs towards a ventricle-like phenotype [231]. Therefore, it can be 
assumed that this is also the case in the human EHM model. hEHM that were treated 
with H1152P from the beginning developed a lower force of contraction than those in 
which treatment was started after three days of consolidation, and in both force of 
contraction was decreased compared to control tissues. Consistent with these 
findings, force of contraction of ROCK inhibitor-treated rEHM consisting of neonatal 
CMs was unchanged compared to control, but higher than force of contraction of 
both H1152P-treated hEHM, although the rat and human model cannot be compared 
that easily. Therefore, it was hypothesized that inhibition of ROCK signalling 
influences not only ECM synthesis and turnover in engineered tissues, but also 
impacts the maturation of CMs in EHM.  
 
 
5.6 Conclusion and perspectives 
In conclusion, this study showed that ROCK1 and ROCK2 are indeed important 
players in the transdifferentiation from cardiac fibroblasts to myofibroblasts. Utilizing 
a neonatal rat cardiac fibroblast culture, it was demonstrated that downregulation or 
inhibition of ROCK1 and ROCK2 resulted in (I) a disturbed actin cytoskeleton and 
reduced formation of higher order actin structures; (II) enhanced adhesion; (III) an 
ambivalent influence on migration; (IV) reduced proliferation. Moreover, the important 
cell cycle regulatory proteins p21 and CDK7 were identified as potential new targets 
for ROCK1 and ROCK2. However, further critical experiments need to be performed 
for verification and identification of the exact phosphorylation site. Furthermore, it 
was shown that inhibition of ROCK activity affects viscoelastic and contractile 
properties of ECT and EHM, which could possibly be due to a change in ECM 
composition, as well as an impairment of CM maturation. Additional experiments 
utilising ROCK1 and ROCK2 knockdown cFBs or CMs would provide evidence 
whether the effect of ROCK inhibition on contractility of EHM is mainly due to an 
effect on cFBs, CMs, or both. It is also of great importance to further determine 
selective function of ROCK1 and ROCK2, i.e. using conditional ROCK1 and ROCK2 
depletion in cFBs or CMs in mice. There is growing evidence that ROCK1 and 
ROCK2 play an important role in the development of cardiovascular diseases. The 
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findings of this study show that this is especially true for the transdifferentiation of 
cFBs to myofibroblasts and hence, the development of cardiac fibrosis. Thus, 
ROCK1 and ROCK2 represent an attractive therapeutic target regarding treatment 
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